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ABSTRACT 
ADDRESSING THE PROBLEM OF STERILE DRUG INJECTING SUPPLY 
ACQUISITION FOR PEOPLE WHO INJECT DRUGS 
Barbra A. Cave 
December 13, 2019 
This dissertation contains five chapters, including three manuscripts, covering 
harm reduction and some of the challenges people who inject drugs (PWID) face in their 
effort to reduce the risk of injection drug-related harms through sterile injecting supply 
acquisition and use. Chapter One discusses some background related to PWID and 
provides an overview of the issues addressed in this dissertation. Chapter Two includes a 
literature review covering the harm reduction concept, important aspects of syringe 
exchange programs as a harm reduction tool, and the social determinants of health model 
as a potential tool for future research. Chapter Three is a two-phase study that examines 
the problem of syringe and drug injecting equipment sharing and reuse among PWID 
participating in a syringe exchange program. This study explores the scope of the 
problem, then uncovers reasons contributing to syringe sharing and reuse behavior. 
Findings are applied to the social determinants of health model, with results 
demonstrating a number of social determinants that influence PWID behavior. In Chapter 
Four the author highlights approaches to sterile drug injecting supply acquisition used by 
PWID and presents policy alternatives. Finally, there is a discussion of a case study and 
v
C
description of  how nurses can ethically support harm reduction strategies for PWID. 
Chapter Five contains a summary of findings and recommendations for future work.
vi
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CHAPTER I 
INTRODUCTION & OVERVIEW 
       Injection drug use is an increasing problem both worldwide and in the United States. 
From 2004 to 2014, the United States saw an 89% increase in the rate of opioid injection 
(Zibbell et al., 2018). Rates of any drug injection increased 76% over the same time 
period (Zibbell et al., 2018). People who inject drugs (PWID) are at risk for a multitude 
of negative consequences. Social consequences may include loss of employment, family 
disruptions, and loss of housing. Legal consequences may include arrest and prosecution, 
and confiscation of drugs and paraphernalia. Perhaps the most severe consequences are 
related to health. PWID experience high rates of skin and soft tissue infections, blood 
stream infections leading to endocarditis and/or sepsis, and acquisition of infectious 
disease such as hepatitis C virus (HCV), hepatitis B virus (HBV), and human 
immunodeficiency virus (HIV) (CDC, 2019; Des Jarlais, 2017; Havens et al., 2013; 
Zibbell et al., 2018). These negative health consequences lead to significant morbidity 
and mortality among PWID, and are costly to the healthcare system. 
         Harm reduction is a set of tools and strategies aimed at reducing the harms caused 
by drug use, and careful attention is paid to PWID. Harm reduction can take place in any 
setting—from healthcare provider offices, addiction care centers, syringe exchange 
programs (SEPs), and more (Hawk et al, 2017). In the United States, one example of 
increased efforts towards harm reduction has taken place through increasing numbers of 
SEPs. Kentucky has the most SEPs of any states, and has increased the number of them 
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from one in 2015, to 69 in 2019 (KDPH, 2019). As the number of programs grow not 
only in Kentucky but nationwide, it is important to understand how PWID interact with 
and participate in such programs. Program evaluation and data tracking are SEP best 
practices, and they may provide clues to models that are working well as well as identify 
potential issues. In 2017, a SEP in Kentucky surveyed its participants as part of this 
process and found reports of continued syringe and drug injecting equipment sharing and 
reuse among their participants (M. LaRocco and W. Crabtree, personal communication, 
January 16, 2017). Sharing of drug injecting equipment undermines some of the 
important health benefits of SEPs. 
         In an effort to understand the frequency of syringe and drug injection equipment 
misuse among SEP participants, a literature search was conducted. Some studies included 
information on syringe sharing for people reporting SEP participation. Luo et al. (2014) 
found PWID in China who had ever participated in SEP had lower odds of having HIV 
(n= 3,494), but they also found people who had attended SEP reported higher rates of 
syringe sharing than non-SEP attendees (OR=1.67, 95% CI=1.19–2.32, p=0.0031). 
Beletsky et al., (2014) found 51.4% of people with inconsistent use of SEP reported 
receptive syringe reuse (n=514, (OR=1.15, 95% CI=0.72-1.81, p<0.01). Bluthenthal, et 
al. (2000) found PWID who had initiated and continued to use SEP reported cessation in 
syringe sharing behavior (204 of 340 PWID). Hartgers, van Ameijden, van den Hoek, 
and Coutinho (1992) reported 24% of routine SEP participants engaged in receptive 
syringe reuse (18 of 75 PWID). Most of the literature was limited to receptive syringe 
reuse. This author wished to  investigate the prevalence of any drug injecting equipment 
misuse (sharing used equipment with others, personally reusing previously used 
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equipment, using equipment previously used by another person, and sharing of sterile 
supplies among PWID engaged SEP), and uncover factors and influences associated with 
such behavior. 
       To prepare for such a study, the author reviewed available literature to better 
understand the perspectives people who use drugs (PWUD) hold of harm reduction. Next, 
the author examined harm reduction best practice guidelines and thoroughly explored 
harm reduction elements, concepts, and principles. As SEPs are a common platform for 
harm reduction, she detailed SEP models and compared them to the best practice 
recommendations. She then highlighted the models used within Kentucky, and explored 
how the social determinants of health (SDOH) model could influence PWID participation 
in a SEP. 
         The SDOH model was originally described by Marmot and Wilkinson in 2006. The 
model appreciates health influences are not merely a result of race, ethnicity, genetics, 
gender or individual behavior, and that actions can be taken to improve the health of 
populations (Marmot & Wilkinson, 2006). The World Health Organization adapted and 
refined the model, and identified key concepts such as economic stability, education, 
health and healthcare, neighborhood environments, and social contexts that include 
employment conditions, social inclusion, public health programs, women and gender 
equity, early childhood development, globalization, health systems, and measurement and 
evidence, and urbanization (WHO, 2019). 
          The SDOH model has been used by nurses caring for people who use drugs 
(PWUD) in an opioid substitution program (Gadbois, Chin, & Dalphonse, 2016). The 
authors recognized limited access to social determinants were substantial barriers to 
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improving the health of people who use drugs in an addiction care program. The authors 
used the SDOH model as a tool for developing a quality improvement program that 
involved nurses and multidisciplinary staff at an urban hospital. Outcomes demonstrated 
improved assessment of SDOH and care coordination for people in the program 
(Gadbois, Chin, & Dalphonse, 2016). 
The author used the SDOH as a theoretical framework to help design and analyze the 
study. Having prevalence estimates of syringe misuse behavior helped uncover the scope 
of the problem, while interviews helped explain what was happening when misuse 
occurred. Subjects were quantitatively surveyed and/or qualitatively interviewed using a 
focused ethnographic approach. The study was approved by the University Institutional 
Review Board, and a certificate of confidentiality was obtained from the National 
Institutes of Health to help protect this vulnerable population. Subjects were recruited 
using convenience sampling from an urban SEP in a southern state. Four themes 
uncovered behavioral/situational factors associated with drug injection equipment 
misuse. Each theme was explored using the SDOH model and examples of determinants 
were identified in the data. 
          After uncovering the scope of drug injecting equipment sharing and reuse among 
the sample and learning which SDOH impact program participation in terms of visit 
frequency and supply limitations, the author sought to explore alternative methods of 
drug injecting supply acquisition, and describe how support for harm reduction is an 
important ethical undertaking for nurses caring for PWID. Alternative methods included 
secondary exchange (receiving sterile supplies from someone who attended a SEP), 
pharmacy syringe sales, injection supply vending machines, and trade or drug dealer sales 
5 
(where the dealer supplies sterile equipment in trade or as an outright sale). Policy 
alternatives aimed at increasing access to sterile drug injecting equipment were explored. 
Alternatives included supply vending machines, SEPs on mobile units, formal support for 
secondary exchange practices, elimination of restrictive syringe distribution models 
within SEPs, and increased support for supply sales within pharmacies. A case study 
example of policy alternatives in action described how the situation in Kentucky’s SEPs 
could improve through elimination of supply distribution limits and bolstering pharmacy 
syringe sales and increased harm reduction support from pharmacists. Informing PWID 
on ways to access sterile injecting supplies is an ethical nursing activity, and the 
principles of harm reduction are in line with the American Nursing Association (ANA) 
Code of Ethics (2015). Harm reduction is supported by the ANA, and resources are 
available to assist them in incorporating principles into patient care (ANA, 2018). 
          The role harm reduction plays in mitigating the negative health consequences for 
PWID is especially clear in SEPs. Uncovering and exploring the SDOH’s impact on the 
ability of PWID to fully participate in harm reduction is important. The work of this 
author described some of the problems faced by PWID in accessing sterile injecting 
supplies, and provided evidence on the estimation of syringe and injecting equipment 
misuse among PWID already engaged in harm reduction services. Future work should 
identify effective strategies in overcoming SDOH barriers and finding ways to achieve 
positive change through policy alternatives. 
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CHAPTER II 
EXPLORING HARM REDUCTION, SYRINGE EXCHANGE PROGRAMS, AND 
SOCIAL DETERMINANTS OF HEALTH: A LITERATURE REVIEW 
Overview 
Introduction: Kentucky is leading the nation in new cases of hepatitis C virus (HCV) 
infection and is at substantial risk for a widespread human immunodeficiency virus (HIV) 
outbreak. These risks are directly tied to the ongoing opioid epidemic, with the 
Appalachian region of the United States demonstrating the highest rates of injection drug 
use. Syringe exchange programs (SEP) are a form of harm reduction aimed at reducing 
drug-related harms, including the spread of infectious disease and the development of 
skin infections and endocarditis. Syringe exchange programs are widely available across 
Kentucky, but people who inject drugs (PWID) may be underutilizing their services. The 
social determinants of health (SDOH) model may help explain PWID behavior in the 
context of SEP participation and drug injection equipment misuse. The purpose of this 
review is to describe harm reduction, syringe exchange programs, and SDOH model to 
guide future research aimed at uncovering what influences PWID decisions regarding 
drug injection equipment misuse. Methods: A systematic review of literature using 
PubMed (MEDLINE) and CINAHL were used to briefly synthesize what is known about 
PWID perceptions of harm reduction and best practices in SEP. Results: PWID have 
positive perceptions of harm reduction but may remain at risk for acquiring HCV and/or 
HIV infection through inconsistent use of harm reduction approaches and full utilization 
7 
of SEP services. SEP services in the region are not following best practices in limiting 
distribution quantities of supplies. The SDOH model may help explain why PWID are 
unable or unwilling to avoid high-risk injection practices, such as sharing used injecting 
equipment when faced with supply restrictions. Future research should examine the 
degree of injecting equipment misuse among SEP participants, and describe what 
influences PWID’s decisions regarding exclusive use of sterile equipment from SEP 
using SDOH as a framework.  
8 
Background 
Hepatitis C virus (HCV) is spread through blood-to-blood transmission and may 
lead to severe morbidity from chronic liver disease, cirrhosis, liver failure, and cancer; in 
some cases, it leads to death or organ transplantation. Hepatitis C virus infection may 
lead to complications or worsening diseases outside of the liver, including lymphoma, 
membranoproliferative glomerulonephritis, lichen planus, porphyria cutanea tarda, and 
insulin resistance (Ansari, Henderson, Stott, & Parr, 2017; Barsoum, William, & Khalil, 
2017; Desbois & Cacoub, 2017; El-Maadawy et al., 2016; Garcovich, Garcovich, 
Capizzi, Gasbarrini, & Zocco, 2015). Hepatitis C virus infection is the most common 
blood borne disease in the world (Shepard, Finelli, & Alter, 2005). There are an estimated 
170 million people worldwide infected with the virus, representing 2-3% of the world’s 
population (Averhoff, Glass, & Holtzman, 2012). More than 350,000 people die each 
year due to complications resulting from HCV infection (Averhoff et al., 2012). 
In the United States, an estimated 5.2 million people are infected (Chak, Talal, 
Sherman, Schiff, & Saab, 2011). Similar to global distribution of HCV, prevalence rates 
vary state-to-state, and mirror the ongoing issues related to injection drug use. For 
example, the U.S. Appalachian region, which includes Tennessee, Ohio, Virginia, and 
Kentucky, opiate prescribing was exceptionally high. This same region is now faced with 
an HCV epidemic that is perpetuated through the increased use of injected heroin in 
response to changes in opiate prescribing laws (Christian, Hopenhayn, Christian, 
McIntosh, & Koch, 2010; Stephens & Havens, 2013).  The primary means of acquiring 
HCV is through injection drug use, but exposure is possible through accidental needle 
sticks, blood transfusions performed before 1992, having unregulated tattoos, men who 
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have sex with men, transmission from mother-to-baby during pregnancy, and through 
healthcare-related procedures (Abdelwahab & Ahmed Said, 2016; Koneru et al., 2016). 
Human immunodeficiency virus (HIV) is transmitted via blood-to-blood, in utero, 
and sexual contact. Infection with HIV may lead to the development of other diseases 
through opportunistic infection (HCV, Herpes zoster, Cytomegalovirus, Shigella, 
Syphilis, M. tuberculosis, Leprosy, Pneumocystis jiroveci, Scabies, Trichomonas, etc.), 
malignancies (Kaposi sarcoma, Hodgkin’s lymphoma, anal carcinoma, etc.), and chronic 
disease (cardiomyopathy, cerebral vasculitis, sarcoidosis, Guillain-Barre syndrome, 
Grave’s thyrotoxicosis, etc.) (Lucas & Nelson, 2015). 
An estimated 35 million people worldwide are living with HIV; 2.3 million are 
newly infected each year and 1.6 million die annually (Lucas & Nelson, 2015). In the 
United States, approximately 1.1 million people are living with the virus (CDC, 2019). 
The majority of new HIV cases are due to sexual transmission, but injection drug use 
may lead to HIV infection (CDC, 2019; Des Jarlais, 2017). In 2016, an estimated 9% of 
new HIV cases were linked to injection drug use (Avert, 2019). Similar to HCV, the 
prevalence of HIV in the United States varies by region. The Southern states made up 
52% of new HIV cases in 2017, even though they make up less than 30% of the United 
States Population (CDC, 2019). 
Significance 
In general, HCV is more transmissible than HIV, especially among people who 
inject drugs (PWID) (Havens et al., 2013). Syringe exchange programs (SEP) are one of 
many harm reduction tools used to help stop the spread of infectious diseases like HCV 
and HIV. In areas without SEP services, PWID are understandably vulnerable to 
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acquiring one or both infections because sterile injecting supplies are difficult to obtain, 
and injection practices are risky due to lack of harm reduction education (Havens et al., 
2013). In Kentucky, SEP services began in 2015 in Louisville in an effort to combat the 
growing opioid injection and HCV epidemics. In 2016, the Louisville Metro Department 
of Public Health and Wellness (LMDPHW) SEP began receiving reports from clients that 
they were sharing or reusing used drug injecting equipment despite their participation in 
the program (M. LaRocco and W. Crabtree, personal communication, January 16, 2017). 
What was unclear was how often this behavior occurred, and what the driving forces 
behind it were. In review of literature, few studies reported on the prevalence of sharing 
of used syringes among participants in a SEP (Luo et al., 2014; Beletsky et al., 2014; 
Bluthenthal, 2000; Hartgers, van Ameijden, van den Hoek, & Coutinho, 1992), and no 
literature was found examining prevalence personal syringe reuse or sharing of used 
equipment with others among PWID already engaged in SEP services. The spread of 
infectious disease is of high concern to all of Kentucky’s SEPs and those impacted by the 
opioid epidemic, and it is well understood that syringe sharing and reuse are the primary 
proponents of disease propagation within networks of PWID (Havens et al., 2013). 
The purpose of this literature review is to describe the concept of harm reduction 
and PWID perceptions of it in order to better understand if PWID have already identified 
issues with harm reduction affecting the potential for syringe misuse; to describe SEP 
best practices as a means of harm reduction; and to explore the utility of the social 
determinants of health model as a framework to guide future research aimed at 
uncovering what factors influence SEP-participating PWID’s decisions regarding drug 
injection equipment misuse. Understanding the interplay between PWID perception, SEP 
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best practices, and SDOH barriers may help future work with PWID to fully engage in 
SEP services and limit syringe and drug injecting equipment misuse. 
Harm Reduction 
The concept of harm reduction evolved during the early 1990s in response to the 
acquired immunodeficiency syndrome (AIDS) epidemic. The concept was defined in 
1995 by Single, who states “harm reduction focuses on reducing the consequences of 
drug use rather than eliminating drug use,” (Single, 1995, p. 288) and its applications 
were described in the 1999 Canadian policy paper, Harm reduction, concepts and 
practice: A policy paper (Riley, 1999). Harm reduction involves working with people 
who use or abuse substances such as illicit drugs or alcohol, as well as policy makers, law 
enforcement personnel, addiction specialists, and healthcare providers with a goal of 
reducing the adverse physical and social harms associated with substance use (Des 
Jarlais, Friedman, & Ward, 1993; Erickson, 1995; Gold, 2009). 
The primary harm reduction tool is use of a non-judgmental approach to provide 
straight-forward education, then allow the person using drugs to make their own 
decisions (Gold, 2009; Single, 1995). Harm reduction is meant to provide behavioral 
choices based on facts, which encourages substance users to exercise their autonomy to 
potentially reduce social or physical detriment (Bartlett, Brown, Shattell, Wright, & 
Lewallen, 2013). This approach is used for other stakeholders such as policy makers and 
providers to reduce stigma and effect policies to enhance services to the targeted 
population. In removing judgement and stigma, people who use drugs (PWUD) may be 
more responsive to their health needs, are more likely to have access to, enter, and 
receive appropriate addiction treatment, and may overcome difficult situations (Bartlett et 
12 
al., 2013). It is important to understand that PWUD often feel stigmatized and 
undeserving when interacting with healthcare providers; developing a sense of trust 
through fidelity, competence, honesty, confidentiality, and strong connections with 
healthcare providers and others who support PWUD increases their sense of trust 
(Treloar, Rance, Yates, & Mao, 2016). 
Eight principles for harm reduction practice have been described by the Harm 
Reduction Coalition (2019). See Table 1. These principles serve as a flexible guide for 
creating goals, taking action, and general considerations for PWUD. Harm reduction 
strategies include syringe exchange programs, medication assisted therapy, supervised 
injection sites, injection supply vending sites (also known as syringe vending sites), peer 
exchange services, and more. 
Table 1 
Principles of Harm Reduction 
Principle 
1 Accept that drug use is part of reality, but work can be done to minimize its 
effects. Drug use should not be ignored, nor condemned.  
2 Understand that drug use encompasses a continuum of behaviors, from severe 
abuse to complete abstinence, and that there are safer ways of using drugs. 
3 Cessation of all drug use is not a criterion for measuring a successful policy or 
intervention; consider individual or community quality of life as a criterion for 
success. 
4 Encourage a non-judgmental and non-coercive approach to providing services 
(such as syringe exchange programs) in an effort to assist PWUD and their 
communities to reduce drug-related harm. 
5 Encourage PWUD to have a voice in the creation of programs and policies meant 
to benefit them, rather than having programs and policies created for them 
without input. 
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Table 1 (continued). Principle
Principle 
6 Recognize PWUD are their own primary actors in reducing harms of their own 
use, and this encourages them to share information and support each other. 
7 Many social inequalities affect PWUD’s vulnerability and capacity to effectively 
manage drug-related harms. 
8 Harm reduction does not attempt to minimize or ignore the real threats and 
dangers associated with drug abuse, whether the drugs used are licit or illicit. 
Note. (HRC, 2019). 
As harm reduction principles are applied to new or expanding areas, knowing that 
PWUD/PWID recognize the importance of the concept is important. Perceptions of harm 
reduction among PWID have been reported in the literature. A systematic review using 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidance is shown in Figure 1. PubMed and CINAHL databases were searched without 
time limits for articles published in English and in the United States using search terms 
“harm reduction,” “people who inject drugs,” and “perception.” Titles and abstracts were 
screened for relevance to the perception of harm reduction programs among PWID.  
Table 2 displays details from the included studies. Three of the four studies are 
qualitative and nature, and one was a cross-sectional survey. 
    Allen et al. (2019) qualitatively interviewed SEP participants in West Virginia and 
determined those PWID found the SEP trustworthy, and had demonstrated value in 
disease and overdose prevention (n=27). In rural Virginia, Baker et al. (2019) 
quantitatively assessed community stigma of PWID by evaluating whether subjects felt 
PWID were strong versus weak, deserving versus worthless, and if addiction was seen as 
a disease versus a choice, where stigma is a negative perception held by others about a 
population. Scores were compared to scores of community harm reduction support and 
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compared to the stigma measures. The authors determined subjects who felt more stigma 
towards PWID were less likely to support community harm reduction measures such as 
SEP, while support for SEP was strongest among those who believe the program helps 
reduce the spread of disease. A group of Chicago PWID participated in Carlberg-
Racich’s (2016) study which sought to determine if they were interested in receiving 
harm reduction education as part of their HIV care, and how they perceived harm 
reduction approaches. Subjects were supportive of harm reduction, and even expressed 
enthusiasm; however, some reluctance to disclose their substance abuse status with their 
provider was also present. In Philadelphia, Harris et al. (2018) qualitatively explored 
PWID perceptions of supervised injection facilities, while also exploring where PWID 
prefer to inject (i.e. at home, abandoned houses, or secluded public space), and what 
factors lead to such a preference (n=42 PWID and 20 healthcare providers). The authors 
found PWID were fully supportive of supervised injection facilities as a harm reduction 
approach in mitigating the risks of drug injection in unsanitary conditions, and reported 
that PWID also recognize the benefits to public health and safety with their use. 
Results from all studies generally indicated that PWID in the United States 
perceive harm reduction in a positive light, whether its principles are delivered in a 
healthcare setting, supervised injection facility, or SEP. Holding a positive view of harm 
reduction is important for PWID because it may influence their willingness to participate 
SEPs. Participants in Allen et al (2019) anticipated a positive experience with harm 
reduction in terms of safer injection counseling and supply provisions; Baker et al. (2016) 
hope PWID participating in comprehensive harm reduction programs are able to 
experience increased community support of harm reduction measures. Even when 
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support for harm reduction exists, PWID remain vulnerable to pressures to engage in 
syringe sharing and misuse (Allen et al. 2019). Nonetheless, PWID and crack cocaine 
smokers remain vested in harm reduction programs and optimistic about their potential to 
reduce drug-related harms, even if it is difficult to discuss ongoing drug use with 
healthcare providers (Carlberg-Racich, 2016). . 
Although there appears to be consensus among these studies, many questions 
remain unanswered. For example, how do perceptions of harm reduction compare among 
different PWID populations (rural versus urban, those with easy SEP access versus those 
with difficulty accessing SEP) and how perception of harm reduction might change when 
multiple types of programs are available. Another question to ask is why do some PWID 
have negative perceptions of harm reduction practices? Understanding how PWID 
perceive harm reduction programing may help tailor programs to meet needs at the local 
level, leading reinforced positive outcomes for PWID. 
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Figure 1.  PRISMA flow diagram showing search results for articles discussing 
perceptions of harm reduction among PWID in the United States. 
Records identified through 
database searching 
(n = 65) 
S
c
r
e
e
n
in
g
 
In
c
lu
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
c
a
ti
o
n
 
Records after duplicates removed 
(n = 53) 
Records screened 
(n = 53) 
Records excluded 
(n =49) 
Not related to perception 
of harm reduction 
(n=21) 
Study conducted outside 
of the United States 
(n=28) 
Full-text articles 
excluded, with reasons 
(n = 1) 
Study conducted outside 
of the United States 
Studies included in 
qualitative synthesis 
(n = 4) 
Full-text articles 
assessed for eligibility 
(n = 5) 
17 
Table 2 
Description and Results of Studies Exploring PWID Perception of Harm Reduction in the United States 
Citation Population, 
Location 
Study Design Description Findings 
Allen, S.T., Grieb, S.M., 
O’Rourke, A., Yoder, R., 
Planchet, E….Sherman, 
S.G. (2019). 
Understanding the public 
health consequences of 
suspending a rural syringe 
exchange services 
program A qualitative 
study of the experiences 
of people who inject 
drugs. Harm Reduction 
Journal, 16(33). doi:
10.1186/s12954-019-
0305-7 
Adult PWID in 
Kanawha County, 
West Virginia 
Qualitative semi-
structured 
interviews 
analyzed with an 
iterative constant 
comparative 
technique. Data 
were collected in 
September 2018. 
A convenience 
sampling strategy 
was used, 
although the 
authors did not 
explicitly state it.  
The Kanawha-
Charleston Health 
Department opened a 
SEP in December 2015. 
Due to community-level 
and political upset about 
the SEP, the 
sociopolitical 
environment changed. 
This led to unfavorable 
laws/regulations for the 
SEP, forcing it to operate 
outside of best practices. 
The SEP ultimately 
suspended services due 
to these circumstances in 
March 2018. This study 
explored the public 
health implications of the 
SEP closure, and 
includes data on the 
perceptions of SEP as a 
harm reduction strategy.  
Sixteen male and 11 female 
PWID participated in the study 
(n=27). The majority (n=21) 
utilized the SEP. Participants 
described their participation at the 
SEP and held a favorable 
perception of the harm reduction 
strategies used within the 
program. Participants described it 
as a trustworthy program, and 
highlighted positive attributes 
including the importance of 
disease and overdose prevention. 
The study discusses implications 
at the public health level due to 
the SEP closure. This study 
funded by the Bloomberg 
American Health Initiative at the 
Johns Hopkins Bloomberg School 
of Public Health. 
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Table 2 (continued). 
Citation Population, 
Location 
Study Design Description Findings 
Baker, L.S., Smith, W., 
Gulley, T., & Tomann, 
M.M. (2019). Community 
perceptions of 
comprehensive harm 
reduction programs and 
stigma towards people 
who inject drugs in rural 
Virginia. Journal of 
Community Health. doi:
10.1007/s10900-019-
00732-8 
Adults in 
Dickenson County, 
Virginia. Sample 
includes PWID 
and non-PWID.  
Cross-sectional, 
community-based 
participatory 
research study 
using a Likert-
scale survey with 
one open-ended 
question 
administered via 
the internet or in-
person from June 
to August 2018. 
A convenience 
sampling strategy 
was used for 
recruitment. 
Investigators aimed to 
assess community 
perceptions of harm 
reduction programs and 
stigma toward PWID in 
Dickenson County, 
Virginia, which is 
considered a rural 
community. Assessment 
of categorical 
perceptions of PWID 
(strong v. weak, 
deserving v. worthless, 
addiction is a disease v. 
choice) were compared 
to ranked level of 
support for harm 
reduction programs. 
One hundred fifty-three people 
participated, and 112 of them 
completed the study online. Ten 
percent of respondents identified 
as PWID (current or former), and 
50% knew a PWID friend or 
family member. Respondents who 
reported high levels of stigma 
towards PWID were least likely 
to support harm reduction. 
Respondents who believed harm 
reduction programs could reduce 
the spread of infectious disease 
expressed a significant, positive 
correlation with support for 
programs, demonstrating a 
positive perception of harm 
reduction. This study was 
supported with funds from the 
Healthy Appalachia Institute at 
the University of Virginia’s 
College at Wise. 
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Table 2 (continued). 
Citation Population, 
Location 
Study Design Description Findings 
Carlberg-Racich, S. 
(2016). Harm reduction 
interventions in HIV care: 
a qualitative exploration 
of patient and provider 
perspectives. PeerJ, 4. 
Doi: 10.7717/peerj.1932 
HIV care providers 
and HIV patients 
with active 
substance use 
disorder in 
Chicago, Illinois 
Qualitative 
phenomenological 
study using semi-
structured 
interviews. 
Convenience and 
snowball sampling 
strategies were 
used. Peer 
debriefing and 
member-checking 
were employed.  
Harm reduction 
strategies may be 
employed in clinical 
care settings, such as 
HIV clinics, but little is 
known about how 
patients and clinicians 
perceive incorporation 
of such training into 
practice. The 
investigator sought to 
explore such perceptions 
and develop 
implications for 
practice.  
Thirty-one patients and seven 
clinicians participated in the 
interviews. All patients used 
heroin and/or cocaine, but not all 
injected. Patients were generally 
receptive to receiving harm 
reduction counseling in the 
clinical setting, and most agreed 
provision of sterile drug use 
equipment would be helpful. 
Some patients (n=16) were not 
comfortable disclosing their drug 
use to their clinicians due to fear 
of being labeled, shame, or 
negative messaging. Providers 
were supportive of using harm 
reduction strategies in clinical 
practice, but time constraints and 
lack of familiarity were seen as 
barriers. Overall, patients who use 
drugs were receptive to having 
harm reduction counseling and 
supplies incorporated into clinical 
care. This study was partially 
funded by the Sherri Aversa 
Memorial Dissertation Fund. 
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Table 2 (continued). 
Citation Population, 
Location 
Study Design Description Findings 
Harris, R.E., Richardson, 
J., Frasso, R., & 
Anderson, E.D. (2018). 
Perceptions about 
supervised injection 
facilities among people 
who inject drugs in 
Philadelphia. 
International Journal of 
Drug Policy 52, 56-61. 
doi: 
10.1016/j.drugpo.2017.11.
005 
PWID and 
healthcare 
providers recruited 
from a SEP in 
Philadelphia, 
Pennsylvania 
Qualitative free 
listing ethnographic 
exercise and semi-
structured 
interviews were 
used. Convenience 
sampling and SEP 
staff referral served 
as recruitment 
strategies. 
Two studies in the 
United States (in San 
Francisco and Rhode 
Island) demonstrated 
quantitative PWID 
support for supervised 
injection facilities 
(SIF). This study aimed 
to qualitatively explore 
PWID support for such 
facilities, and explored 
the motivations for 
drug injection location 
among PWID in 
Philadelphia. 
Nine men and 10 women 
participated in the interview 
process (n=19). Forty-two PWID 
and 20 healthcare providers 
participated in the free listing 
exercise. PWID in this study 
support SIF as a positive harm 
reduction intervention, although 
they prefer to inject at home. 
They note the importance of 
clinical supervision to reduce 
overdose death. PWID perceived 
SIF as a potential “safe haven,” 
where they could perform 
injection in a calm environment 
without fear of assault or arrest. 
PWID perceived SIF value within 
the community by reducing 
community exposure to discarded 
injection equipment. PWID 
perceive social and environmental 
factors such as homelessness and 
distance as influencers on their 
degree of SIF use. The authors 
did not report a funding source 
for this study. 
Note:  SEP= Syringe Exchange Program. SIF= Supervised Injection Facility.
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Syringe Exchange Programs 
Syringe Exchange Programs (SEP) are based on harm reduction principles where 
a non-judgmental approach to the program participant is paramount (Treloar et al., 2016). 
They have been active in the United States since 1988 (Des Jarlais et al., 2015; Fernandes 
et al., 2017). Syringe Exchange Programs (SEP) services include provision of injecting 
supplies such as sterile water, cotton filters, tourniquets, cookers, syringe disposal 
containers, and an appropriate syringe selected based on the injector’s needs (i.e. the 
quality of their veins), with the expectation of syringes being returned to the site for safe 
disposal without re-use or sharing (Hagan, Pouget, & Des Jarlais, 2011). Counseling 
includes discussion of safer injection techniques, such as using alcohol swabs before 
injecting and using antibiotic ointment and an adhesive bandage afterward; discussion on 
infectious disease exposure risk; and the importance of safe syringe disposal (Hagan et 
al., 2011). An important aspect of SEP is the ability of the SEP staff, which is often 
comprised of certified drug and alcohol counselors or peers who also used drugs, to 
identify the aperture (or window of opportunity) for the person who injects drugs to 
consider entering addiction treatment, and the level of trust the programs can build with 
people who inject drugs (PWID) seeking care (Treloar et al., 2016). Counselors can make 
referrals for drug treatment, discuss drug treatment strategies and past experiences, and 
help match an addiction care program to the person’s needs. 
Disease prevention is a critically important aspect, and many SEP sites offer a 
combination of HIV, HCV, and sexually transmitted infection screening for participants, 
as recommended by the Centers for Disease Control (CDC, 2012). Syringe exchange 
program services are increasingly available in the United States, but not all PWID access 
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such programs, or access them inconsistently for a variety of reasons (Davis et al., 2019). 
People who use drugs engaging in harm reduction programs have a general understanding 
of the public and personal health benefits these programs promote, and are supportive of 
them (Bozinoff, Small, Long, DeBeck, & Fast, 2017; Otiashvili et al., 2019). 
Best practice guidelines for SEP exist, and cover aspects from effective practices 
to community engagement. In order to identify available best practices for SEP, a 
systematic review was conducted. PubMed (MEDLINE) was used as the primary 
database as it includes a diversity of literature across health and social sciences, including 
addiction. Using search terms “syringe exchange program,” or “syringe service 
program,” or “needle exchange program,” or “needle supply program,” and “best 
practice,” 37 articles were found. Two additional publications were located using a hand 
search strategy in an effort to locate resources from professional organizations. Figure 2 
displays the PRISMA flow diagram, including reasons for excluding articles. Articles 
were included without time limitations, and if they were written in English, and stated 
best practices or provided guidelines for SEP services. Table 3 lists specific best practices 
from each guidance document. 
The most comprehensive guidance on harm reduction appears to be Strike et al.’s 
2006 document created with the help of the Ontario Needle Exchange Coordinating 
Committee, a representative committee from the Ontario Needle Exchange Network. The 
document covers SEP efficacy, factors involved in starting a program, recommendations 
for best practices surrounding supply handling and disposal, distribution of equipment, 
delivery models, and provision of education (including safer sex and overdose 
prevention), social support, medical care, law enforcement relationships, and tools for 
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program evaluation. Using the 2006 guidelines as a backbone, Strike and Watson (2017) 
modified recommendations to better fit the needs of crack cocaine smokers in terms of 
supply needs, and pipe distribution. The New York City Department of Mental Health 
and Hygiene 2009 guidance document offers best practice guidelines for SEPs across the 
United States. Content includes guiding principles, outlines SEP practices to avoid, 
recommendations for data collection and program evaluation, recommendations to 
improve SEP access and availability, how to address state paraphernalia laws related to 
SEP supplies, and additional recommendations such as encouragement of syringe 
pharmacy sales and prescribed syringes. The authors encouraged the Institute of 
Medicine to  study SEP best practices, and the National Institutes of Health to convene a 
consensus panel for the purpose of identifying research gaps. Having best practices for 
SEP is as important as recognizing which practices to avoid. Understanding the 
challenges of SEP operators and SEP participants face in maximizing best practices while 
avoiding potentially damaging practices is critical for PWID as individuals, as well as 
ensuring a successful SEP operation. 
All three best practice documents consider the importance of having low-barrier 
access to sterile drug injecting supplies. Education is a critical piece, including 
discussions on safer sex, disease transmission, and safer use practices. The best practice 
guidelines also consider program evaluation to be an important administrative component 
as a means to track supply distribution and interactions with clients, and to ensure client 
needs are being met. The guidance documents discuss the importance of providing a 
referral mechanism or actual healthcare in the SEP setting as many PWUD have health 
concerns such as abscesses, cellulitis, burns, and more. Linkage to addiction are, 
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including opioid substitution treatment, is another common recommendation. None of the 
guidance documents operating costs or detail all budgetary considerations. 
Figure 2.  PRISMA flow diagram demonstrating systematic search results for best 
practices for syringe exchange programs. 
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25 
Table 3 
Best Practice Guidelines for Syringe Exchange Programs 
Source Country Description Recommendations 
Strike, C. & Watson, 
T.M. (2017). Education 
and equipment for 
people who smoke 
crack cocaine in 
Canada: progress and 
limits. Harm Reduction 
Journal, 14(1). doi: 
10.1186/212954-017-
0144-3 
Canada Among people who smoke crack 
cocaine, a number of negative 
health outcomes exist including 
oral ulcerations, oral cuts, burns, 
and increased risk for HIV and 
HCV. Harm reduction for people 
who smoke crack has lagged 
behind such programming for 
PWID. This work was not funded. 
-Provide safer equipment (including stems, 
mouthpieces, screens, push sticks) 
-Do not require clients to return used equipment 
-Provide the quantity requested by the client 
-Have both pre-packaged kits and individual pieces of 
equipment available 
-Integrate programming into existing SEP 
-Provide safe disposal options 
-Provide other harm reduction supplies (condoms, 
lubricant) without quantity limits 
-Educate clients on safer use, risks of sharing smoking 
supplies, and safer sex 
Provide multiple locations for disposal 
Strike, C., Leonard, L., 
Millson, M., Anstice, 
S., Berkeley, N. & 
Medd, E. (2006). 
Ontario needle 
exchange programs: 
Best practice 
recommendations. 
Toronto: Ontario 
Needle Exchange 
Coordinating 
Committee, 2006. 
Canada This 266-page document, available 
in PDF at 
http://www.ohrdp.ca/wp-
content/uploads/pdf/Best_Practice
s_Report.pdf, was developed by 
the 2006 committee as part of the 
Ontario Needle Exchange Network 
(ONEN). Roles of ONEN are 
wide-spread, and include 
education of providers, 
communities, and PWUD. This 
work was funded by Health 
Canada. 
Brief best practices for SEP (p.39): 
-Provide sterile injecting equipment in quantities 
requested by clients without requiring them to return 
used equipment or limiting the number of new 
equipment provided.  
-Encourage clients to return used syringes for safe 
disposal 
-Educate clients about the risk of using non-sterile 
supplies 
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Table 3 (continued). 
Source Country Description Recommendations 
New York City 
Department of Health 
and Mental Hygiene 
(NYC DHMH) (2009).  
Recommended best 
practices for effective 
syringe exchange 
programs in the United  
States. Retrieved from 
https://harmreduction.o
rg/wp-
content/uploads/2012/0
1/NYC-SAP-
Consensus-
Statement.pdf 
United 
States 
A group of SEP experts convened 
to develop this consensus 
document outlining best practices 
for SEPs, and points out factors 
which may limit SEP 
effectiveness.  
Effective SEPs share the following characteristics: 
Low threshold access to services by 
-Maximum number of locations and available hours 
-Anonymity of participants 
-Minimize administrative requirements of participants 
Promote secondary exchange 
-Train and support peer educators 
-Do not limit syringe quantities 
Address local PWID population 
-Adapt activities and services to local needs 
Provide/coordinate health and social services as needed 
Include community stakeholders in creating supportive 
SEP environment 
Practices to Avoid: 
-Supplying syringes that may only be used once 
-Requiring one-for-one exchange 
-Limiting participants to a specific geographic location 
-Restricting supply volumes 
-Requiring identification of participants 
-Requiring unnecessary data collection 
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SEP best practice guidance encouraged implementing the least restrictive supply 
distribution model possible (NYC DHMH, 2009; Strike et al., 2006). There are multiple 
models of SEP equipment distribution. They include a one-for-one exchange, less than 
one-for-one, one-for-one plus, and needs-based system of supplying and returning used 
syringes. Table 4 provides a brief description of each model. While the protocol of all 
SEPs involves supply of syringes, provision of other drug injecting equipment varies 
from program-to-program. For example, Bixler et al., (2018) evaluated SEPs in 
Kentucky, West Virginia, and North Carolina and found wide variation in services 
beyond supplying sterile syringes. Kentucky had the most operating programs with 
access to injecting supplies (such as cookers, filters, water, alcohol swabs, tourniquets), 
while West Virginia and Kentucky were nearly equal on the percentage of programs 
supporting HIV and HCV screening, reproductive planning, and education. Regardless of 
the syringe distribution model used, PWID have access to sterile syringes when visiting 
SEP (Bixler et al., 2blu018; Bluthenthal et al., 2007). 
Table 4 
Syringe Exchange Program Distribution Models 
Model Program Description 
One-for-one exchange For each used syringe returned, participants may replace it 
with a sterile one.  
Less than one-for-one 
exchange 
Like one-for-one, this program requires an exchange of 
used-for-new syringes, but the syringes must originate 
from the SEP. For example, a syringe from a pharmacy can 
be returned after use, but it will not count towards a sterile 
replacement because it did not come from the specific SEP. 
One-for-one plus 
exchange 
Participants may exchange the number of syringes returned 
and take an additional pre-determined amount in an effort 
to build up a stable supply of sterile equipment between 
SEP visits. For example, a participant may return 20 
syringes and have 30 provided in exchange. 
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Table 4 (continued). 
Model Program Description 
Needs-based Participants may obtain the number of sterile syringes 
needed without regard to the number of syringes returned. 
Participants are not limited on the frequency of their visits. 
This approach is considered best practice. 
Note: (Bluthenthal et al., 2007; Sherman et al., 2015). 
In Kentucky, many SEP programs are limited to a one-for-one syringe exchange, 
despite the fact this is not considered best practice (NYC DHMH, 2009; Sherman et al., 
2015). This model may lead to syringe reuse and sharing among people unable to return 
an adequate number of used syringes (KDPH, 2015; NYC DHMH, 2009). In cities like 
Vancouver and San Francisco, where transitions from a one-for-one model to a needs-
based model of syringe distribution occurred, there were increases in SEP participation, 
the number of syringes distributed and returned, and an increase in new SEP clients 
(Sherman et al., 2015).  However, a one-for-one model may serve as a stepping stone for 
communities initially reluctant to provide SEP services, and those with budget limitations 
(KDPH, 2015). Ultimately, SEPs provide sterile injection supplies to the PWID 
community, but the impact on reduction in HCV/HIV incidence may be limited due to 
continued syringe sharing and misuse behavior and the one-for-one approach does not 
adequately cover PWID needs (Bluthenthal et al., 2007). 
SEPs operating under a one-for-one plus model distribute syringes based on the 
number returned, but supply an additional set quantity per visit. This model is the 
intermediary between a strict one-for-one policy and a needs-based model (Bluthenthal et 
al., 2007). SEPs using a needs-based approach may serve as an important aspect in 
increasing SEP reach through secondary exchange (Brothers, 2016). The Centers for 
Disease Control (CDC) recommends a sterile syringe be used for each injection, and a 
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needs-based model of syringe exchange ensures PWID have a sterile syringe for each 
injection (2019). 
What is happening in Kentucky’s Syringe Exchange Programs? 
The United States has seen a surge in injection drug use and new cases of 
hepatitis C virus (HCV) infection since 2004, with sharp increases in both beginning in 
2010 (Campbell et al., 2017; Zibbell et al., 2018; J. E. Zibbell et al., 2015). Outbreaks 
and clusters of human immunodeficiency virus (HIV) infection, which are also associated 
with injection drug use, have occurred across the United States during the same time 
frame (Bradley et al., 2019; Moorman, Krolikowski, Mathis, & Pack, 2018; Peters et al., 
2016). One of the most serious HIV outbreaks occurred in Scott County, Indiana in 2014-
2015, where 181 people were diagnosed with HIV (Peters et al., 2016). Among them, 167 
(92.3%) were co-infected with HCV. Nearly 88% of the cases were directly tied to 
injection opioids (Peters et al., 2016). The Scott County HIV/HCV outbreak served as a 
wake-up call for the United States to recognize the risk of acquiring infectious diseases 
among vulnerable PWID populations, especially in Appalachia, where SEP had been 
illegal (Des Jarlais et al., 2015; Van Handel et al., 2016). 
In response to the serious HIV/HCV outbreak in Scott County, Indiana and 
subsequent recognition of Kentucky’s vulnerability to experiencing a similar event, the 
Kentucky state legislature passed an emergency provision legalizing SEP in March 2015 
(Bixler et al., 2018; Goodin, Fallin-Bennett, Green, & Freeman, 2018). The first SEP to 
begin operating in Kentucky opened on June 5, 2015 in Louisville, where it continues to 
operate as the state’s largest and most comprehensive SEP. By October 28, 2019, 69 
SEPs had been authorized or became operational in Kentucky, and Kentucky has more 
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SEPs than any other state (see Figure 3). Each SEP required the approval of local (city), 
county, and state officials are under the jurisdiction of local health departments or their 
partners (Bixler et al., 2018).  
 
Figure 3. Kentucky map showing location by county of SEP in operation or approved as 
of August 2, 2019. Counties in green (n=54) are among the top 220 counties in the 
United States considered vulnerable to an HIV outbreak, similar to that seen in Scott 
County, Indiana (KCHFS, 2019).  
Kentucky SEPs are required to track the number of syringes distributed and 
returned, basic participant demographic factors, type of substance(s) injected, HIV and 
HCV screening tests, and if available: naloxone education and distribution, fentanyl test 
strip distribution and results, and linkage to social, addiction, or healthcare services. Over 
time, the Louisville Metro Department of Public Health and Wellness SEP, which uses a 
one-for-one plus syringe distribution model, began receiving participant reports of 
syringe sharing and used equipment reuse in their efforts to collect required data (W. 
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Crabtree, personal communication, January 12, 2017). Syringes represent a common 
piece of equipment shared or reused; however, cookers, cotton filters, and tourniquets are 
also susceptible to misuse and may spread infectious disease (Kim, Jin, McFarland, & 
Raymond, 2015; Palmateer et al., 2014). Although many SEPs across the United States 
support sharing of sterile equipment through peers (secondary exchange), it is not a 
formally endorsed practice at any of Kentucky’s SEPs (Behrends et al., 2017). 
The LMDPHW SEP promotes weekly visits through their efforts to supply 
participants with enough injecting equipment to last one week. However, participants are 
not required to return at any particular time interval. For first-time participants who do 
not have any used syringes to dispose of, 50 syringes are distributed along with all other 
needed equipment according to protocol (T. Nunez, personal communication, July 10, 
2019). The participant has the option to return as many times as needed, as frequently as 
needed, to build up their syringe supply to last one week or more. Anyone returning 
syringes for disposal may take that number of sterile syringes, plus 20 if desired. If a 
returning participant is not able to exchange any used syringes, up to 20 syringes are 
distributed with the expectation they will begin to build their sterile supply once more 
through return visits. Notably, choice of substance and degree of dependency impacts the 
daily frequency of drug injection. PWID may inject opioids, cocaine, methamphetamine 
or other substance recreationally (less than once per week), and need very few syringes. 
However, those dependent on cocaine may need 20 or more syringes per day. At the 
LMDPHW SEP, 62.8% of participants reported injecting five or more times each day 
(Cave, 2019). Some participants exchange more than 400 syringes at their weekly visits, 
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suggesting that they are not only acquiring supplies for their own use, but supplies for 
others (Cave, 2019). 
Overall, SEP programs in Kentucky follow most of the best practices for such 
programs as described in the New York City guidance (2009). They provide client 
anonymity, an assortment of sterile supplies (not just syringes), education, infectious 
disease testing, linkage to healthcare, social services, and addiction care, and make use of 
harm reduction principles in their approach to PWID in the programs. One of the largest 
gaps between SEP best practices and SEP operations in Kentucky is the distribution 
quantity limitation where participants may not receive enough sterile supplies. Although 
there is no limit on the number of visits a client can make to the SEP, this quantity 
limitation per visit may be a major barrier in ensuring clients are not sharing or reusing 
supplies. The social determinants of health model may help identify SEP participation 
barriers, and provide a framework for SEPs to positively adapt their programs to improve 
access. 
Social Determinants of Health Model 
The social determinants of health (SDOH) are a group of factors that influence the 
health, well-being, and longevity of people and has been used worldwide as a framework 
for improving population health and reducing health disparities. Based primarily on the 
work of Sir Michael Marmot, the SDOH were recognized as overarching influencers on 
individual health, and health outcomes and that these influencers occur across a social 
spectrum (Marmot & Wilkinson, 2006). That is, health influences are not merely a result 
of race, ethnicity, genetics, gender or individual behavior. Marmot recognized a 
multitude of factors that influence health, and developed the SDOH model to help enable 
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action strategies to improve the morbidity and mortality of populations (2006). Marmot 
and Wilkinson’s (2006) work linked social structure to health through a number of 
factors, and they presented applied examples and supporting evidence about how such 
factors could be influenced by experiences in early childhood, culture, socioeconomic 
factors and genetics (Marmot & Wilkinson, 2006). Figure 4 presents a social 
determinants of health model.  
Figure 4. Social determinants of health demonstrating the link between social structure and 
pathways which may lead to health or disease (Brunner & Marmot, 2006, p. 9). 
Over time, the model has been refined and adapted. The World Health 
Organization (WHO) (2019) describes SDOH as 
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…the conditions in which people are born, grow, live, work, and age. These
circumstances are shaped by the distribution of money, power, and resources at 
global, national and local levels. The social determinants of health are mostly 
responsible for health inequities- the unfair and unavoidable differences in health 
status seen within and between countries. 
The World Health Organization (WHO) identifies key concepts within SDOH of 
economic stability, education, health and healthcare, neighborhood environments, and 
social contexts that include employment conditions, social inclusion, public health 
programs, women and gender equity, early childhood development, globalization, health 
systems, and measurement and evidence, and urbanization. Each of these key concepts 
are described in detail through publications and policy interventions that provide 
blueprints for communities (WHO, 2019). 
The United States Department of Health and Human Services (HHS) Healthy 
People 2020 health objectives use five SDOH factors: economic stability, education, 
health and healthcare, neighborhood and built environment, and social and community 
contexts to frame objectives that lead to social and physical environments that promote 
good health (HHS, 2014). Each health determinant contains a subset of factors that may 
influence an individual’s chance for optimal health (see Table 5). 
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Table 5 
Social Determinants of Health and Key Influencing Factors for Healthy People 2020 
Social Determinant Factors 
Economic stability Employment, food insecurity, housing instability, poverty 
Education Early childhood education/development, enrollment in higher 
education, high school graduation, language and literacy 
Health/Healthcare Access to health care and primary care, health literacy 
Neighborhood/ built 
environment 
Access to foods that support health eating patterns, crime and 
violence, environmental conditions, quality of housing 
Social/ Community 
contexts 
Civic participation, discrimination, incarceration, social 
cohesion 
Note: Adapted from Healthy People 2020 (HHS, 2014). 
The SDOH are easily applied to PWID. Van Handel et al. (2016) noted how the 
PWID of Scott County, Indiana suffered from unemployment and poverty, had low 
educational attainment, and had poor life expectancy. People who inject drugs are often 
subject to incarceration, which may further increase their risk of acquiring HIV and/or 
HCV (Stone et al., 2018). Low health literacy among PWID is common, especially when 
trying to understand how their substance use may impact their liver health (Marshall, 
Grebely, Dore, & Treloar, 2017). In the healthcare setting, PWID are often stigmatized 
and discriminated against (Bartlett, Brown, Shattell, Wright, & Lewallen, 2013; Couto, 
Cruz, Salom, Maravilla, & Alati, 2018). 
The SDOH model has been used by nurses caring for PWUD in an opioid 
substitution program in New Bedford, Massachusetts, an area similarly affected by both 
HCV and opioid epidemics (Gadbois, Chin, & Dalphonse, 2016) like Kentucky. The 
authors recognized limited access to housing, food, and primary healthcare were 
substantial barriers to improving the health of PWUD in an addiction care program. The 
authors used such SDOH as a tool for developing a quality improvement program that 
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involved nurses and multidisciplinary staff at an urban hospital. Outcomes demonstrated 
improved assessment of SDOH and care coordination for people in the program 
(Gadbois, Chin, & Dalphonse, 2016). 
Applying the SDOH model in future research may help us understand the driving 
forces behind SEP participant’s inconsistent use of sterile injecting equipment with each 
injection episode. The SDOH disparities that may lead some to injection drug use may be 
the same disparities that limit full use of SEP and adoption of harm reduction strategies. 
Assessing, addressing, and mitigating potential factors that may be uncovered through 
research will support PWID to more fully utilize SEP services, thus, reducing the risk of 
additional spread of HIV, HCV, and other negative health outcomes. It may also help 
facilitate care coordination between the SEP and other community services. 
Conclusion 
Understanding why PWID engaging in SEP services are not consistently using 
sterile drug injection supplies for 100% of injection events needs to be explored. It is 
clear that sharing or reusing old injecting equipment propagates infectious disease, 
among other health-related and social harms. Kentucky is leading the nation in new cases 
of HCV infections, and is at risk for having simultaneous clusters or a widespread 
outbreak of HIV and HCV co-infection in PWID (Van Handel et al., 2016). Kentuckians 
now have access to SEP throughout the Commonwealth, but there continues to be syringe 
and drug injection equipment reuse and sharing among PWID participation in such 
programs. It is unclear if this dilemma is related to lack of best practice in syringe 
distribution models in Kentucky’s SEPs, where the majority of programs operate under a 
one-for-one model. Research is warranted to explore the degree of drug equipment 
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misuse among SEP clients, and to understand what factors contribute to such behavior. 
The SDOH model may offer some explanation as to why PWID continue to share or 
reuse drug injecting equipment. The SDOH model may provide a framework for future 
action in addressing the problem. 
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CHAPTER III 
EXAMINING SYRINGE AND INJECTING EQUIPMENT SHARING AND REUSE 
AMONG PEOPLE WHO INJECT DRUGS PARTICIPATING IN A SYRINGE 
EXCHANGE PROGRAM 
Overview 
Introduction: People Who Inject Drugs (PWID) are at risk for negative health 
consequences. Harm reduction strategies like syringe exchange programs (SEP) help 
reduce consequences like skin and soft tissue infections, infectious disease, and 
endocarditis through provision of sterile injecting supplies and education. These services 
benefit PWID, yet some SEP participants continue to share or reuse (misuse) drug 
injecting equipment. Although much is known about the behaviors and motivations for 
PWID to misuse equipment outside of SEPs, little is known about the factors influencing 
those who utilize SEP services who continue misuse injecting equipment. This study 
aimed to examine the prevalence of injection equipment misuse with others, personal 
injection equipment reuse, and to describe the factors leading to equipment misuse 
among people participating in SEP. Methods: The study utilized a two-phase approach. 
A cross-sectional survey was used to estimate the prevalence of injecting equipment 
misuse. Qualitative interviews explored behaviors and motivations leading to injection 
equipment misuse. Both strategies utilized convenience sampling at a single urban SEP in 
an Appalachian state. Results: There were 111 surveys were collected. Participants were 
21-68 years old, with mean age of 37.8 years (SD=10.7). Most were male (59.5%, n=66); 
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87.4% (n=97) were white; 45.9% (n=51) visited SEP monthly; and 33.3% (n=37) weekly. 
The majority (69.4%, n=77) reported providing used equipment to others. Nearly 30% 
(n=32) reported reusing their old equipment, and 37.8% (n=42) reported using equipment 
that was used by another person. Fifteen individuals participated in interviews. The 
average age was 39 (SD=11.6; range=28-60); 53% (n=8) were male, 40% (n=6) were 
female, one was transgender; and 87% were white. Four themes uncovered 
behavioral/situational factors associated with drug injection equipment misuse: sterile 
supply stability issues; high-risk behaviors or attitudes; having the right equipment at the 
right time; and trying to be safe. Conclusion: Injection equipment sharing and reuse is 
common, even among people participating in a SEP. There are reasons for sharing and 
reuse that are related to social determinants of health. Multiple opportunities exist for 
SEPs to develop interventions and strategies to reduce the prevalence of injecting 
equipment misuse. 
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Background and Significance 
 People who inject drugs are at highest risk for acquiring and spreading hepatitis C 
virus (HCV) infections, representing up to 80% of HCV infection cases in the United 
States (Martin, Vickerman, Dore, & Hickman, 2015; Zibbell et al., 2018). Through harm 
reduction practices such as syringe exchange programs (SEP), also known as needle 
exchange programs and syringe service programs, participants are educated on best 
practices for reducing the risk of infection and other harms, and provided with sterile 
injecting supplies. Despite provision of free sterile injecting supplies and education, there 
exists some degree of syringe re-use or sharing among SEP participants (Bluthenthal et 
al., 2004; Bozinoff, Small, Long, DeBeck, & Fast, 2017; Ksobiech, 2006). Such behavior 
is counter-productive to SEPs and harm reduction as a whole because it allows for spread 
of infectious disease, skin and soft tissue infections, or blood stream infections. Although 
behaviors of people who inject drugs (PWID) are well described and the need for harm 
reduction through SEP is clearly supported in literature, little is known about the factors 
and behaviors influencing SEP participants who might continue to share or re-use 
syringes, and the prevalence of such behavior (Allen, Ruiz, Roess, & Jones, 2015; 
Dunleavy et al., 2017; Hagan, Pouget, & Des Jarlais, 2011; Hesamizadeh, Sharafi, 
Rezaee-Zavareh, Behnava, & Alavian, 2016; Mateu-Gelabert et al., 2014).  
 This risky sharing and re-use of supply behavior occurs within all PWID 
communities. Ksobiech (2006) conducted a meta-analysis demonstrating syringe sharing 
behaviors were reduced among SEP participants compared to those who do not 
participate, but the prevalence of syringe sharing was not reported in this analysis.  In a 
broader search conducted in the fall of 2018 using PubMed (MEDLINE), CINAHL, 
41 
EMBASE, and PsychINFO, including worldwide articles using search terms “people who 
inject drugs”, “syringe exchange program,” “needle exchange,” “syringe or needle 
misuse”, “re-use”, and “sharing”, only one article was found (Kim, Jin, McFarland & 
Raymond, 2015). Kim et al. (2015) determined the rate of unsafe injecting practices (such 
as using a syringe previously used by another person, 34.2% [95% CI 24.2-45.2] in 2005 
to 12.5% [95% CI 7.5-18.6] in 2012, p<0.001, n=570) had declined, and rates of syringe 
acquisition from pharmacies (17.8% in 2005 to 32.1% in 2012, p<0.001) or SEP (80.7% 
in 2009 to 86.5% in 2012, p<0.022, n=570) had increased. Although some literature 
discusses Secondary Syringe Exchange, which is a practice of visiting SEP to acquire 
equipment and education to be distributed to others outside of the program (Behrends, Li 
& Gibson, 2017), no studies could be found that focused on behavioral factors associated 
with used syringe sharing and personal reuse of equipment by SEP participants 
completed within the past twenty years. 
The purpose of this research was to explore the motivations and behaviors of 
PWID using SEP in a Southern state who share new or used equipment, or re-use 
(hereafter, misuse) syringes and drug injection equipment. Drug injection equipment 
includes syringes, cookers, filters/cotton, sterile water, and tourniquets. The Specific 
Aims are: 1) to examine the daily, weekly, and monthly prevalence of syringe and 
equipment reuse and sharing among PWID participating in SEP; 2) to describe the daily, 
weekly, and monthly personal syringe re-use prevalence; and 3) to identify behaviors and 
motivations leading SEP participants to misuse SEP-provided syringe and/or injecting 
equipment. 
Theoretical Framework 
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The behaviors of many individuals who inject drugs may not reflect application of 
knowledge about the risks of acquiring HIV or HCV infection as a consequence of 
sharing injection equipment or poor sanitation techniques despite availability of SEP and 
sterile syringe supplies through pharmacies (Golub et al., 2007; Kim et al., 2015; 
Palmateer et al., 2014). Furthermore, PWID with access to SEP services may not 
exclusively obtain syringes from a sterile source such as SEP or a pharmacy; they may 
buy them from drug dealers, share with friends, or use a diabetic’s discarded insulin 
syringes (Wejnert et al., 2016). This behavior may be due to a multitude of factors that 
have not been previously identified due to the paucity of research regarding PWID 
engaged in SEP services. Although some hypotheses have been identified such as 
defensive behavior in which PWID may prioritize immediate injection to avoid 
withdrawal symptoms, or social norms that encourage sharing a drug preparation among 
multiple users in a group setting (Bozinoff et al., 2017; Golub et al., 2007). The lack of 
research warrants the use of a health model that allows for a complex view of factors that 
may serve as barriers or facilitators of these behaviors. Therefore, applying a model 
focused on the social determinants of health (SDOH) is appropriate. 
The SDOH model was developed by Marmot in the 1990s. The SDOH model 
described the ways in which economic and social standing could influence health and 
health outcomes among individuals and populations. Marmot and Wilkinson’s (2006) 
SDOH model included determinants such as social structure, social environment, 
employment, health behaviors, and material factors while considering the influence of 
early life experiences, genetics, and culture in the overall health or disease status of 
populations. This socioeconomic model has been adapted across the world, including the 
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World Health Organization (WHO) which uses the SDOH as a guide to impact the health 
of diverse populations, even nations. The United States Department of Health and Human 
Services (DHHS) adopted a list of five determinants on which the Healthy People 2020 
health objectives are based. Both the WHO and DHHS models break down the 
determinants into factors, which can be used as assessment tools and a framework for 
policy development. Table 1 displays the DHHS disparities and factors. 
Table 1 
Social Determinants of Health and Key Influencing Factors for Healthy People 2020 
Social Determinant Factors 
Economic stability Employment, food insecurity, housing instability poverty 
Education Early childhood education/development, enrollment in higher 
education, high school graduation, language and literacy 
Health/Healthcare Access to health care and primary care, health literacy 
Neighborhood/ built 
environment 
Access to foods that support health eating patterns, crime and 
violence, environmental conditions, quality of housing 
Social/ Community 
contexts 
Civic participation, discrimination, incarceration, social 
cohesion 
Note: Adapted from Healthy People 2020 (DHHS, 2014). 
For the purposes of this research, the DHHS (2014) SDOH model used in Healthy 
People 2020 was applied to the findings. This SDOH model is specific to the United 
States, and the objectives related to SDOH positively impact PWID (see Appendix A). 
Exploration of the factors within the five social determinants may hold the most potential 
for understanding the risky PWID behavior as it relates to decisions about syringe and 
drug injecting equipment misuse, and also serve as a framework for the development of 
future interventions. 
Methods 
Study Design 
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This was a two-phase study which consisted of quantitative (survey) and 
qualitative (individual interview) approaches. A two-phase approach was best strategy to 
quantitatively estimate the frequency of the behaviors of interest, to qualitatively uncover 
reasons for them, and to avoid the problem of overlooking important evidence while 
increasing understanding of the problem (Pluye & Hong, 2014). Cross-sectional surveys 
were used to estimate frequency of behaviors in a given population, and was considered 
the most appropriate approach to measure drug injecting equipment misuse in this 
sample. Cross-sectional surveys are a common quantitative approach to assessing 
prevalence, and may also be used for measuring attitudes, validation studies for different 
instruments, and assessing reliability (Kesmodel, 2018). 
          Qualitative methods, particularly a focused ethnography approach, has been used to 
study people who use drugs worldwide, and have examined multiple types of illicit drugs 
and/or alcohol, and routes of administration (Ambrogne, 1999; Dilkes-Frayne, 2016; 
Fast, Kerr, Wood, & Small, 2014; McNeil, Kerr, Lampkin, & Small, 2015; Pagano et al., 
2018; Wall, 2015). Studies have centered around identifying barriers for drug users 
seeking harm reduction (McNeil et al., 2015), how networks of drug use are created and 
social norms developed at multi-day music festivals (Dilkes-Frayne, 2016), and how 
people of an ethnic minority who use drugs support each other in addiction treatment 
(Pagano et al., 2018). Focused ethnography intends to uncover reasons for behaviors, 
problems with existing programs, and potential solutions to such problems through 
“mapping of the cognitive world of a culture; a cultures’ shared meanings, semantic 
rules” (Polit & Beck, 2017, p.249; Rashid, Hodgson, & Luig, 2019; Wall, 2015). 
Interpretation of data resources, such as interviews, photos and field observations help 
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researchers form the response to the question, “What is happening here?” amongst a 
culture or subculture (Wall, 2015). 
Setting 
The study was conducted within a mid-sized metropolitan city in the southeastern 
United States with a population of 602,000. This community is served by the Syringe 
Exchange Program. The metropolitan Syringe Exchange Program (SEP) opened in June 
2015. From opening through April 2018, the SEP served more than 15,000 unique 
clients. Table 2 displays demographic details for the SEP participants. In February 2017, 
the SEP staff informally surveyed participants and found 29% shared syringes (n=497; Y. 
Chen, personal communication, 2018). 
Table 2 
Syringe Exchange Program Participant Demographics for All Clients 6/10/15 to 4/30/18 
Number Percent 
Clients Total Clients 15,325 
Return Clients 6,834 44.59 
Age (years) 17-29 3,443 32.61 
30-39 4,387 41.55 
40-49 1,834 17.37 
50-59 703 6.66 
60+ 191 1.81 
Gender Female 3,945 38.41 
Male 6,291 61.25 
Transgender - ID Female 18 0.18 
Transgender - ID Male 17 0.17 
Sex Orientation   Straight/Heterosexual 9,351 90.42 
Gay/Lesbian 380 3.67 
Bisexual 606 5.86 
Questioning 5 0.05 
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Table 2 (continued). 
Number Percent 
Race White 9,589 92.52 
Black/African American 469 4.53 
Native American 89 0.86 
Pacific Islander 12 0.12 
Asian 15 0.14 
Other 190 1.83 
Hispanic Yes 248 2.44 
No 10,118 97.59 
Employed Yes 3,452 33.36 
No 6,897 66.64 
Insurance Medicaid 5,944 56.21 
Medicare 348 3.29 
Private/Commercial 1,140 10.78 
Other 72 0.68 
Uninsured 2,796 26.44 
Drug(s) Used Heroin 8,446 79.88 
Other Opioids 370 3.50 
Cocaine 314 2.97 
Methamphetamine 3,202 30.28 
Methadone 9 0.09 
Suboxone 10 0.09 
Other Drugs 183 1.73 
Drug Use Frequency   1 or 2 
Per Day 3 or 4 
1,430 
2,500 
13.52 
23.64 
    5 or more 6,644 62.83 
Note. Unpublished data provided courtesy of the staff of the SEP. The SEP received 
anecdotal reports from PWID using their services that they are sharing or reusing 
syringes and supplies (M. LaRocco and W. Crabtree, personal communication, January 
16, 2017). Drug(s) used does not equal 100% as some participants may report 
simultaneous heroin and methamphetamine use. 
Projection of human subjects. 
The University Institutional Review Board reviewed and approved this study. A 
waiver of informed consent was approved for quantitative survey participants; full 
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informed consent was required for interviews. Pseudonyms were used for consent 
signatures. A National Institutes of Health Certificate of Confidentiality was approved for 
participants in the qualitative interviews. Both quantitative survey and qualitative 
interview participants remained anonymous to the investigator. 
Sample 
Inclusion criteria for the quantitative portion of this study were as follows: 
subjects must be a SEP participant (having visited the SEP at least once), age 18 years or 
older, a current injection drug user, agreeable to participation, and had not previously 
taken the survey. They were excluded from participation if they were under 18 years, 
even if they were an emancipated minor, had taken the survey previously, or if they could 
not read or understand English. Subjects completed the self-administered survey with an 
investigator nearby to clarify any questions as needed.  
For the qualitative interviews, subjects were eligible to participate if they were a 
SEP participant who reported at least monthly attendance over a six-month period, was 
aged 18 years or older, able to provide informed consent, a current injection drug user 
with at least six months of reported injection drug use experience, and any reported 
history of syringe misuse. Participants were eligible even if they were recreational drug 
users who did not inject on a regular basis. Subjects were excluded if they were under age 
18, unwilling to be audio-recorded, could not speak or understand English, or unwilling 
to provide informed consent. Subjects completing surveys could be included in the 
interviews, and no link was made between the subject’s survey and interview. 
Recruitment. 
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 From February 13 through May 8, 2019, a convenience sample of subjects 
visiting in a metropolitan syringe exchange program were invited to complete the eight-
item survey. Potential subjects were approached by the investigator as they waited for 
SEP services. After a brief introduction and explanation of the study, participants 
reviewed key study information, including study purpose, benefits/risks of participation, 
and alternatives to participation (preamble consent) and decided if they wished to 
participate by completing the survey, or declining. Surveys were self-administered on a 
single sheet of paper and took two-to-three minutes to complete.  
Interview participants were introduced to the investigator by SEP staff or were 
recruited as they waited for SEP services. After the investigator introduced herself, 
potential participants were taken to a private area of the SEP where informed consent was 
completed. Subjects completing the consent were interviewed using an interview guide 
containing questions addressing equipment procurement, motivation and situational 
factors leading to supply sharing, and questions surrounding supply reuse. The interviews 
lasted 15-30 minutes each. Interview subjects were recruited until the newest subjects 
were consistently reporting experiences similar to previous subjects (data saturation). 
Field notes, observations, photographs taken within the SEP, and printed materials 
available in the SEP were collected and reviewed per the focused ethnography guidelines 
of Polit & Beck (2017, p.333).   
Study Procedures 
Cross-sectional surveys were used to quantitatively describe the frequency of 
personal drug injecting equipment reuse, and sharing of new and used drug injecting 
equipment to fulfill aims one and two of the study. The survey was modeled after an 
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informal survey the SEP had distributed to participants in February 2017.  The 
investigator refined the survey based on content expert input and SEP participant 
feedback. The eight-item paper survey consisted of multiple choice and a fill-in-the-blank 
response for age (see Appendix D). Table 3 defines frequencies of behaviors, as listed on 
the survey and use for analysis purposes. Potential participants were approached face-to-
face by the investigator within the SEP and invited to participate in the study. Those 
agreeing to participate reviewed the consent (Appendix E) with the investigator. Any 
questions potential participants had about participating in the study were answered. Those 
agreeing to take part in the study completed the survey on their own. 
Table 3 
Behavior Frequency Definitions 
Never The participant has never engaged in the specified behavior. 
Less Than Monthly The behavior occurs less than once per month. 
Monthly The behavior occurs 1-3 times most months 
Weekly The behavior occurs 1-4 times most weeks 
Daily The behavior occurs 5-7 times most weeks 
One-time semi-structured interviews qualitatively addressed factors and 
motivations around syringe misuse behavior. Interview questions were open-ended and 
conducted one-on-one with the author. Like the quantitative survey, interview questions 
were developed by the investigators and refined by a content expert (see Appendix C). 
These focused ethnography questions explored the culture and environment surrounding 
sterile drug supply acquisition, use, and reuse.  Two pilot interviews were conducted with 
SEP participants prior to formal data collection to ensure clarity of questioning from a 
participant perspective, and to assist the investigator in developing interview skills. All 
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interviews were conducted face-to-face in a private room within the SEP over 15-30 
minutes. The investigator did not have a prior relationship with interview participants; 
participants were informed the interview was part of the author’s dissertation process 
before informed consent was completed.  
Data Analysis 
Quantitative analysis. 
 Quantitative data were analyzed using SPSS version 25.0 (IBM, Armonk, NY). 
Descriptive statistics explored demographic characteristics such as age, gender, ethnicity, 
and frequency of SEP equipment misuse. Frequency of misuse were collapsed into binary 
variables (ever and never) to avoid small cells. Further analysis explored groups using 
Cochran-Mantel-Haenszel tests to detect differences between age and gender across drug 
injecting equipment sharing and reuse. 
Qualitative analysis. 
For qualitative analysis, interviews were transcribed using NVivo Transcribe 
(QSR International, Melbourne, Australia) then verified by the investigator for accuracy. 
Qualitative data management was facilitated with the use NVivo 12 Plus (QSR 
International, Melbourne Australia). Transcripts were not shared with participants due to 
the need to preserve their anonymity and logistical difficulty setting appointments for 
such a purpose. Transcripts were coded line-by-line using an open-coding strategy to 
identify common categories and concepts that may help explain the subculture of people 
who use drugs who participate in a syringe exchange program. Coding was an iterative 
process, with  initial codes such as equipment cleaning, transportation problems, avoiding 
withdrawal, and protection of anonymity identified as important factors. Open coding 
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allows investigators to label concepts and define categories based on properties or 
dimensions in text (Khandkar, n.d.). A second reader helped validate initial codes for 
investigator triangulation (Rashid, Hodgson, & Luig, 2019). Secondary coding grouped 
codes together into themes (Polit & Beck, 2017, pp 574-579) which describe the culture 
surrounding syringe and injection equipment misuse. 
Results 
Quantitative Sample Characteristics 
There were 111 individuals who completed the survey. Table 4 displays 
demographics and overview of syringe misuse behaviors. The age range for survey 
participants was 21 to 68 years with mean age of 37.7 (SD=10.7) and median of 36 years. 
Table 4 
Descriptive Statistics and Estimates of Syringe Misuse Behaviors for Survey Participants 
Survey Item Frequency 
(%) 
Binary 
Frequency (%) 
Gender, n=111 
         Male 
        Female 
66 (59.5) 
45 (40.5) 
Race/Ethnicity, n=110 
     White, non-Hispanic 
     Black, non-Hispanic 
     Hispanic/Latino/Latina 
     Other 
     Missing 
97 (87.4) 
9 (8.1) 
0 
4 (3.6) 
1 
Visit Frequency, n=106 
      First Time 
      Less Than Once Per Month 
      Monthly 
      Weekly 
      Daily 
      Missing 
5 (4.5) 
10 (9.0) 
51 (45.9) 
37 (33.3) 
3 (2.7) 
5 (4.5) 
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Table 4 (continued). 
 
  
Survey Item Frequency 
(%) 
Binary 
Frequency (%) 
Provide Used Equipment to Others, n=111 
      Never 
      Less Than Once Per Month 
      Monthly 
      Weekly 
      Daily 
 
77 (69.4) 
20 (18.0) 
4 (3.6) 
3 (2.7) 
7 (6.3) 
 
Never: 77 (69.4) 
Ever: 34 (30.6) 
Provide New Equipment to Others, n=109 
      Never 
      Less Than Once Per Month 
      Monthly 
      Weekly 
      Daily 
      Missing 
 
46 (41.4) 
16 (14.4) 
19 (17.1) 
17 (15.3) 
11 (9.9) 
2 (1.8) 
 
Never: 46 (42.2) 
Ever: 63 (57.8) 
Personal Reuse, n=110 
      Never 
      Less Than Once Per Month 
      Monthly 
      Weekly 
      Daily 
      Missing 
 
32 (28.8) 
16 (14.4) 
26 (23.4) 
18 (16.2) 
18 (16.2) 
1 (1.0) 
 
Never: 32 (29.0) 
Ever: 78 (70.9) 
Receptive Reuse, n=111 
      Never 
      Less Than Once Per Month 
      Monthly 
      Weekly 
      Daily 
 
69 (62.2) 
5 (4.5) 
13 (11.7) 
6 (5.4) 
18 (16.2) 
 
Never: 69 (62.2) 
Ever: 42 (37.8) 
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Quantitative Findings 
Sharing of new syringe and injection equipment among SEP participants was 
common (n=63, 57.8%) with 28 (25.7 %) reporting the sharing of new supplies with 
others on a daily or weekly basis. Reuse of personally-used drug injecting equipment was 
the most common misuse behavior (n=78, 70.9%), with up to 32.7% (n=36) of 
participants reusing equipment on a daily or weekly basis. Reuse of equipment obtained 
from another individual was reported by 42 (37.8%) survey participants, 30 of whom 
were male. Sharing of used syringes was reported by 34 (30.6%). A higher proportion of 
males under 30 years of age reported using injection drug equipment that was previously 
used by another person (63%, n=19) compared to women, regardless of age (31.3%, n=16 
for women under 30 and 27.6%, n=29 for women 30 years and older), and older men 
(40.4%, n=47). Overall, syringe and injection equipment misuse was a familiar activity to 
many SEP participants. Table 5 displays syringe misuse prevalence by age and gender, 
where no particular form of syringe misuse was significant when stratifying across age 
and gender. 
Table 5 
Bivariate analysis of syringe misuse behaviors stratified by age and gender 
Variable Gender Age 
(years) 
Never Ever Total Chi 
Square 
DF p-value 
Receptive Reuse Male 
Female 
≤ 30 7 12 19 1.373 1 0.241 
>30 29 18 47 
≤ 30 12 4 16 
>30 20 9 29 
Personal Reuse Male 
Female 
≤ 30 3 16 19 0.162 1 0.687 
>30 15 31 46 
≤ 30 6 10 16 
>30 7 22 29 
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Table 5 (continued.) 
Variable Gender Age 
(years) 
Never Ever Total Chi 
Square 
DF p-value 
Sharing Used Male 
Female 
≤ 30 12 7 19 0.351 1 0.553 
>30 33 14 47 
≤ 30 11 5 16 
>30 21 8 29 
Sharing New Male 
Female 
≤ 30 6 12 18 0.004 1 0.948 
>30 23 23 46 
≤ 30 8 8 16 
>30 8 21 29 
Qualitative Sample Characteristics 
Interview participants (n=15) ranged in age from 28 to 60 years; eight were male 
(53%), six were female (40%), and one was male-to-female transgender (7%). All were 
Caucasian (n=13, 87%) except for one African American and one Hispanic. Seven (47%) 
participants self-disclosed a positive HIV or HCV infection status. 
Qualitative Findings 
Line-by-line coding produced 54 codes on the first reading of transcripts. Through 
re-reading and iteration, initial coding was reduced to 35 concepts. The concepts were 
used to develop four themes that help explain syringe and injection equipment misuse 
among people in the SEP. Experiencing sterile supply stability issues and having a high-
risk behavior/attitude were associated with motivations and behaviors or situations that 
made sharing or reusing old equipment likely. Having the proper injecting equipment and 
trying to be safe were themes associated with reduced equipment misuse behavior and 
improved motivation to use only sterile supplies. Major concepts within these themes and 
their related SDOH are listed in Table 6. 
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Table 6 
Major Themes and Associated Social Determinants of Health 
Theme Behavioral, Situational, or 
Motivational Concept 
Related Social 
Determinant(s) 
Sterile supply 
stability issues 
-Transportation problems (n=4) 
-Problems with supply limitations 
        (n=3) 
-Limited SEP locations/hours (n=4) 
-Fear of arrest (n=3) 
Economic stability 
Health and healthcare 
Health and healthcare 
Community context 
High risk 
behaviors or 
attitudes 
-Saving drugs for later use (n=11) 
-Intimate partner sharing (n=10) 
-Ambivalence about using old      
      Equipment (n=10) 
-Not considering sterility of equipment 
      aside from syringe (n=4) 
-Knowing HIV/HCV status (n=12) 
Health and healthcare 
Social context 
Health and healthcare 
Health and healthcare 
Social context 
Having the 
right equipment 
at the right time 
-Using proper equipment for 
      successful, comfortable, sterile 
      injection (n=6) 
-Convenience in getting new supplies    
     (n=4) 
-Wanting to avoid using other’s     
     medical supplies  (n=4) 
Health and healthcare 
Built environment, 
community context, 
economic stability 
Social context 
Trying to be 
safe 
-Cleaning used equipment (n=10) 
-Maintaining adequate stock of sterile 
      Supplies (n=5) 
-Concern for the safety of other PWID 
       (n=9) 
-Concern for personal safety (n=4) 
-Knowing HIV/HCV status (n=12) 
-Concern for public safety (n=2_ 
Health and healthcare 
Health and healthcare 
Social context, health and 
healthcare 
Health and healthcare 
Health and healthcare 
Health and healthcare, 
Community context 
Note: Behavioral or situational concepts are actions or circumstances that influence 
misuse. Motivational concepts are thoughts/feelings/desires that lead to misuse. 
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Sterile supply stability emerged as a theme correlated with the likelihood of sterile 
drug equipment sharing and reuse. Having high risk behaviors or attitudes surrounding 
injection drug use emerged as a theme because participants may disregard infection 
control measures (sterility) due to ambivalence about sharing with sexual partners, or 
because PWID culture suggested that a practice may have been safe or low-risk. Having 
the right equipment at the right time had a positive impact on participants’ use of sterile 
injecting supplies; however, when the proper equipment was not available, reuse of used 
supplies was common. Despite the high-risk nature of injection drug use, participants 
valued safety from both public and personal health views. 
Sterile Supply Stability 
Lack of access to sterile equipment at the time of injection was a significant factor 
in personal drug injecting equipment re-use, receptive syringe re-use, and sharing of used 
equipment with others. Interview participants reported personal equipment reuse was 
commonly practiced when sterile supplies were not immediately available. Participants 
were aware of their need to return to SEP, but may have been unable to do so due to 
transportation difficulties or limited SEP hours, reflective of the economic stability social 
determinant (limited money for transportation) and health/healthcare (SEP is closed). 
Joe finds that limiting supplies to 20 syringes more than what is returned may not 
be enough for some drug injectors. In cases where Ashlee could not make it to the SEP in 
time for a resupply of equipment, she notes “I’ll try to just use them once, but then things 
will come up, and I won’t make it [to the SEP] by the time they close, or whatever else. 
And then I’ll end up going in to my ‘just been used once’ stash in my little container. 
And I’ll end up using it again. Just until I can make it here.” 
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Three SEP participants reported “laziness” as an inhibiting factor in using sterile 
equipment for 100% of injections. Bolivar recognized bacterial contamination of cotton 
filters, but admitted he may reuse them because he is “just being lazy.” Chris explained 
how he and others may not “feel like they can get up and go to the other room to get [a 
syringe]. They get the same one they already used. Most of us think it’s safe, you know. I 
mean, if I used it, I think it’s clean. So why can’t I reuse it again?” 
Motivation to use sterile supplies fluctuates for Joe, who said, “…if I know that 
I’m low, or if I’m out in the field and I don’t have the motivation to get up and go get 
more, then I say, ‘Who cares?’ So, it’s just…it’s petty.” Interestingly, Joe points out a 
low supply and fear of arrest (community context social determinant) contribute to the 
problem of equipment reuse. “If I had more [supplies], you know, the laws would help, 
too. I could carry more with me.” Joe goes on to say, “Because you can’t carry [syringes], 
so I mean if they catch anything on you, then you’re in trouble. So, I don’t want to carry a 
whole bunch of stuff with me. But also, if I went into a situation where I run out, then I’m 
going to have to reuse.” 
The majority of interview participants expressed a strong desire to preferentially 
give away sterile supplies should another PWID be in need, even if it meant depleting 
their personal sterile equipment stockpile. In turn, this leads SEP participants to 
personally re-use their own equipment in order to provide sterile equipment to another 
PWID, reflective of the social context social determinant. Some participants were willing 
to share their used supplies with others when they were personally out of sterile supplies; 
however, attempts to sanitize/sterilize the used equipment took place. 
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Applying the SDOH model to sterile supply stability uncovered how PWID 
utilizing SEP encountered a number of socio-economic factors that limited their ability to 
use only sterile injecting equipment. For Joe, transportation barriers (economic stability 
determinant) limited his ability to consistently access SEP. He was also hastened by fear 
of arrest (community context determinant), as carrying drug paraphernalia is illegal in 
Kentucky. For Ashlee, the SEP operating hours created a barrier (access to healthcare or 
community context determinant). Interestingly, the preference to give away sterile 
supplies to other PWID was an example of the social context determinant, and was as a 
positive form of social cohesion for the recipient. For the equipment provider, however, 
this social cohesion created a barrier to consistent sterile supply access because supplies 
were reused, and they were not necessarily sterilized properly. 
High Risk Behaviors and Attitudes 
Injection drug use is already considered a high-risk behavior, but in the context of 
PWID using SEP services, high risk behaviors and attitudes may occur due to low health 
literacy. One such high risk behavior is the common practice of making a wash, which is 
a common practice described by participants throughout the study. A wash is made from 
collecting used filters such as cottons or cigarette filters, then adding water to release 
leftover drug residue from the original and/or subsequent preparations. A used cooker is 
sometimes kept for the same purpose. Amanda describes a wash: “I just let the drugs 
build up in [the cotton]. If I come up hard one day, I throw a couple of cottons in the 
water, smash them around [then inject the solution].” 
Having a wash available addresses an addicted person’s urgency to use drugs by 
helping them to avoid withdraw symptoms. A wash may provide enough drug to limit 
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withdrawal symptoms long enough for the PWID to obtain a new supply of drugs.  SEP 
participants may save their cottons or cookers for their own wash at another time, or give 
away their used supplies for a wash to another in need. Regardless of who might be using 
a wash, there was a general lack of recognition that bacterial or viral contamination takes 
place with these particular pieces of drug injecting equipment (low health literacy).  Shay 
said she “never even thought about [used cookers] being dirty…I was just thinking 
needles, you know?” And Amanda reflected, “The cookers and things like that; I guess 
I’m probably not careful with those. And I probably should be, because I forget about 
them. You know, you stick a syringe in your cooker, and it’s just the same as, you know 
[the syringe]. You know, and I guess I don’t think of [the cooker] that way.” Shay and 
Amanda’s examples of low health literacy, part of the health social determinant, explain 
why some SEP participants do not hesitate to use a wash, especially the urgency to inject 
is secondary to experiencing unpleasant withdraw symptoms. 
Injecting drugs with an intimate partner appears to be another common high-risk 
behavior driving reuse of drug injecting equipment that was previously used by another 
person. Sharing used equipment with an intimate partner was felt to be relatively safe or 
easy. Kitty reported sharing used equipment from her boyfriend of 10 years: “We were 
always together and I had to keep up with everything in my bag... It’s just easier to mix 
all of our stuff up together, and then you know, draw it up and split it. It was just easier.” 
Liz explains, “It seems different if you actually share with your boyfriend or girlfriend or 
whatever, because you have been together for so long. So whatever one of you has, you 
both have. That’s how I see that.” Shelby reported receiving used equipment from her 
boyfriend, and explained, “A lot of the time we share stuff just because we keep all our 
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stuff together, usually. So, it’s kind of hard to know whose is whose sometimes. If you 
were using, which we do reuse a lot, if we end up reusing [a syringe], it’s hard to know 
who has used it before. Same thing with cottons.” 
Eight interview participants were against the notion of sharing their used 
equipment or receiving used equipment from people outside of an intimate relationship, 
suggesting their degree of health literacy was adequate enough to understand the risk of 
disease transmission from person-to-person through shared equipment. However, those 
with drug injecting intimate partner relationships described ambivalence about re-use and 
sharing with that partner. Amanda and Kitty readily shared with their intimate partners 
because it was easy or convenient, and accepted in the social context determinant.  Others 
still preferred to not share at all with their partners, but might do so when there were no 
supplies or the injection was proving to be difficult. There was no concern for acquiring 
new infectious disease as they both assumed to have the same infection, or no infection at 
all. However, none of the participants appreciated the risk of developing bacterial 
infection as a result of contaminated equipment when asked about it, suggesting an 
element of low health literacy persists despite the social context between injecting 
partners creating a sense of well-being. Participants described feeling safe when injecting 
drugs with an intimate partner. 
For participants who injected with non-intimate partners, it was important to 
know the serostatus of the used equipment provider. Meaning, if the recipient knew about 
the HIV or HCV infection status of the equipment provider, they would consider using 
the non-sterile equipment. From Tim’s perspective, asking about serostatus would 
determine who he may take used equipment from: “Whenever you reuse a syringe of 
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somebody else, depending if you already have hep C or are…basically, if I do use from 
anybody, I know at least a little bit of their background as far as their blood, from 
asking.” Having the same serostatus as an injecting intimate partner was assumed, and 
further contributed to ambivalence in accepting used equipment. From a SDOH 
perspective, understanding serostatus is an important, positive indicator of health literacy. 
The cohesion (social context determinant) between intimate partners appeared to 
contribute to syringe and injection equipment misuse because a sense of convenience 
(Kitty and Amanda) and safety (Ashlee) had developed. When supplies were already in 
the environment, it was convenient for both parties to share. The practice was not 
perceived as high-risk because participants did not appreciate the risk of negative 
consequences beyond the spreading of infectious disease when sharing with their 
partners, and a sense of safety was achieved. For non-intimate partners, sharing of used 
equipment was avoided except when the provider’s infectious disease status was known. 
This, too, is an example of social cohesion. Participants with known HIV or HCV were 
unlikely to give away used equipment to others without the disease. 
Having the Right Equipment 
Comfort during the injection procedure emerged as a theme supporting the desire 
to limit syringe and equipment misuse. Using a filter/cotton helped limit debris from the 
drug preparation process from entering the body and reduced “cotton fever” for Ashlee. 
Several participants suggested that using a filter helped limit dulling of a new needle, 
making for a more comfortable injection. Used cottons become hard, which damages the 
needle bevel. Multiple participants endorsed desire to always use a new syringe in order 
to avoid discomfort while injecting. Recognition that sterile supplies help with injection 
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comfort supports continued behavior of using only sterile equipment. Unfortunately, 
participants reported they were likely to engage in equipment reuse if they ran out of 
supplies, rather than waiting until they could visit the SEP again. 
In some instances, not having the proper syringe available at the time of injection 
may lead to misuse behaviors. This was particularly evident between intimate partners, as 
previously described. In cases of personal reuse, Amber noted how important having the 
proper syringe size was to her in determining if she would reuse one of her personally 
used syringes, “…I actually had a couple of the short ones on accident, and you know, I 
can’t use those.” For cookers, Kitty described how she had adapted her cookers to avoid 
burns before the SEP began carrying cookers with a handle: 
I finally got rid of the spoon when they impounded my car. They took my spoon, 
and then I started coming here and these caps, the big ones that you guys have…So 
I do heroin, and I always put heat to it to cook out as many impurities as I can 
because I still don’t know what I’m sticking in my arm. But, you know, I try to be 
as safe as I can. So, you know the barrettes? The snap barrettes? Like, I bought a 
six pack of Hello Kitty snap barrettes and that’s how I would hold the cap to heat 
it up before they started having ones with handles. I would put that little snap 
barrette on it. 
Having the desired or proper drug injecting equipment helped ensure comfort during 
injection or the drug preparation process. Participants tried to maintain sterile stock of 
their preferred equipment, but some reused old preferred equipment in the setting of non-
preferred sterile equipment if it meant for a more comfortable injection. Having the right 
equipment for injection does not clearly fall within a SDOH. Rather, it speaks to the need 
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for SEP to provide a variety of injecting equipment choices, and the need to provide them 
in adequate quantities. 
Trying to Be Safe 
Unfortunately, syringe and injection equipment misuse and sharing were common 
among interview participants. Participants tried to be safe by avoiding any need to share 
or reuse by always having ample supplies of sterile equipment on-hand. When this was 
not possible, participants continued to convey a sense of the need to be safe from multiple 
perspectives. Most participants attempted to clean equipment before reuse out of concern 
for personal safety and the safety of other PWID. Knowledge of one’s HIV and/or HCV 
status also contributed to perceived safety when reusing or sharing supplies. Secondary 
exchange practices not only helped provide sterile supplies when possible, but also 
allowed SEP participants to disseminate education and best practices to non-SEP PWID. 
According to interview participants, maintaining adequate sterile injecting 
supplies limited their perception of the need to share or reuse equipment. However, if 
supplies were depleted, whether from unexpected secondary exchange or inability to 
return to the SEP, equipment reuse behavior became common. Providing people outside 
of SEP with SEP supplies and education is considered secondary exchange. Bolivar says 
he “will maintain a stockpile whether I'm using much or not at all, for those 
acquaintances of mine. I'm omitting the exchange program” because he understands there 
other PWID who do not use SEP services. Chris feels sterile SEP supplies are in demand, 
“mostly everybody I know comes here. Or you know, gets them from somebody else who 
does come here.” Kitty also supports secondary exchange while noting how important it 
is to inject using sterile supplies: 
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I break the rules of the program and it's pretty messed up. But I pick up syringes 
from a lot of people who live close to where I live, and I bring them back for them 
because they do not have the means to get here, and I bring things back for them. 
 And while that does violate the rules of the program, I... (Pause) I have been in 
situations where I had no way to get syringes, or you know, the things that I needed 
to safely inject... and I just don't want to let people around me be in that same 
situation if I can prevent it. 
Some SEP participants acquire equipment or supplies in order to trade them for drugs or 
sell them for cash. This behavior creates an economy around sterile SEP supplies, which 
speaks to the importance of economic stability. Billy has bartered SEP supplies for drugs: 
I befriended a guy in camp, and he needed some new needles and stuff. And he 
offered to give me some dope if I would come down here, and get some needle 
exchanges, and leave, that for him. So, I come down here and get my little I.D. so 
I can get a needle exchange, and I figured, ‘What?  Why not?’ So, I sat down and 
had him shoot me up the first time, and taught me how to do it myself. So, I've 
been on [heroin] ever since. But he was the reason I came down here. To mainly 
start picking up the needles. 
Billy also said, “Well sometimes I will give them [bartering partners] new stuff still in the 
bag and not ever been used yet... for, you know, if I'm running low on dope or something... 
I'll trade some for a couple of shots of what dope that they got.” Chris recognized the 
supply-and-demand principle: “People with the dope pretty much... like, they can pretty 
much get what they want. A clean [syringe], a dirty [syringe]. They'll find one or they'll 
buy it from somebody who does have one. I've seen that a lot of times. People get it from 
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the [syringe] exchange [program] and sell them on the street. People who don't even use  
[will sell them].” 
 Interview participants preferred to provide sterile equipment to others, but some 
situations could increase the likelihood of a SEP participant sharing used equipment with 
another PWID. For instance, when sterile equipment was not available, interview 
participants described cleaning their equipment before sharing as a sentiment of 
preventing injury, which is a demonstration of positive health literacy. Amanda explained 
she does not “give my syringes away freely. I’m not going to. Those are mine. Those are 
to protect me, and keep me safe. And, unless it’s just a desperate situation for someone 
else. I do not want to give my used things away.” Ashlee was surprised when people 
asked for her used equipment: “It astounds me how many people are so comfortable with 
that, and they don’t even clean them. I know cleaning them with bleach or alcohol, or 
whatever, doesn’t necessarily make it okay. But still, they throw caution to the wind.” 
She attributes the asking behavior to younger injectors:  
The girl I live with, she’s like 23. And a lot of the friends she has that are asking  
for these things a lot are super young, you know, in their early 20s. And I guess  
they just don’t know, just like when I was young and dumb and just careless.  
They haven’t seen all this stuff yet. It hasn’t affected them. So, it doesn’t really hit  
home, and I guess that stuff just comes with age. Just seeing it, and it really  
sinking in. 
When sharing or reuse is necessary, the majority of interview participants 
described a variety of attempts at cleaning or sterilizing their equipment. Those who 
personally re-used items such as filters/cottons made no attempts to clean them before the 
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next use. For cookers, Tim might use an alcohol swab before use. Shay would reuse her 
cooker until “it looked dirty.” In some cases, however, no cleaning procedures took 
place. Joe prepared a single syringe to be used throughout the day, without regard to the 
possibility of it becoming contaminated with bacteria or debris. Although most 
participants reported attempts at cleaning procedures for syringes they intended to re-use 
or share, they did not consider the cleanliness or sterility of other equipment. 
Disappointingly, most cleaning procedures described by participants were not in 
line with the Centers for Disease Control recommendations (CDC, 2018). The CDC 
recommends only pure bleach with water rinses for sanitizing used syringes. Tim 
reported using hand sanitizer; five participants suggested using alcohol as a rinsing agent. 
Only Bolivar was able to describe a cleaning procedure close to the CDC 
recommendations, which uses a series of bleach and rinse water. Interestingly, 
participants describing any type of sanitizing procedure also noted that they did not 
believe their methods to be effective in prevention HCV and/or HIV transmission. Ashlee 
thought, “I know cleaning them with bleach or alcohol, or whatever, doesn’t necessarily 
make it okay.” Shay said, “…I read that you can use alcohol and it will clean the needle, 
but I don’t trust it.” 
Trying to be safe was very important to Tom, who refuses to share his used 
equipment with anybody, regardless of circumstance, because he has human 
immunodeficiency virus (HIV). He explains, “I wouldn’t give them used ones. That’s just 
something I won’t do. Just because it’s such a big deal to me. And I don’t know if I could 
deal with it very easily if I knew that somebody became [HIV] positive because they used 
one of my used syringes and didn’t clean it properly or something. I mean, I know that’s 
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a risk they’re taking, and they’re assuming. But I would still feel responsible.” Chris, who 
has hepatitis C virus infection, prefers to know the serostatus of people he may share one 
of his used syringes with: “They usually got it, too. It’s not like I don’t have anything 
more, but, you know, I wouldn’t just give it to someone that didn’t have it. And I hate for 
people to reuse… I would give anybody [a new] one if I had it instead of selling it or 
reusing it. Just for the fact of the health issues.” Tom and Chris’ regard for the safety of 
other PWID because of their own infections further support the concept that PWID are 
interested in the safety of others when it comes to syringe and equipment sharing 
practices.   
Trying to be safe demonstrated a strong sense of community among PWID. It 
demonstrated elements of positive and negative health social determinants (clarifying 
serostatus before sharing versus ineffective cleaning procedures for used equipment), as 
well as social contexts that may lead to equipment misuse. Understanding the need to 
provide sterile equipment for personal safety and the safety of other PWID was consistent 
with social cohesion (community context determinant) and the desire to maintain a safe 
environment through proper syringe disposal via secondary exchange (neighborhood 
environment determinant). For people like Tom, trying to be safe also meant he had good 
health literacy (health determinant). 
Limitations 
There are several limitations to this study. The study was conducted for a 
specified period and this sampling strategy may have missed people who visit SEP 
outside this time period. Convenience sampling allowed for subject self- selection which 
may have failed to identify additional social determinants influencing drug injecting 
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equipment misuse, as well as failed to capture additional motivations, situations, and 
behaviors by those who did not participate in the study. This study took place in an urban 
setting where the majority of subjects in both the qualitative and quantitative portions 
were white. Differences were not explored between people injecting different substances, 
making comparison of behaviors specific to heroin, methamphetamine, or other 
substances beyond the scope of this study. 
Conclusion 
Syringe and drug injection equipment sharing and reuse are common among 
people participating in SEP. There appears to be common SDOH that lead to personal 
reuse, receptive reuse, sharing of used equipment, and sharing of sterile equipment 
despite participation in SEP. The most common SDOH influencing drug injecting 
equipment misuse was social context, wherein PWID see themselves as a community 
sharing common needs and practices. These behaviors appear to be similar to those who 
are not engaging in SEP services, including injecting with an intimate partner and having 
friends who inject (Munoz et al., 2015). Health and healthcare determinants were also 
identified, mainly in terms of low health literacy regarding disease transmission risk for 
misusing non-syringe equipment such as filters and cookers. 
Having consistent access to sterile supplies through SEP helped most participants 
avoid personal and receptive reuse, as well as limited sharing of used equipment. It 
helped facilitate secondary exchange or providing various pieces of sterile equipment to 
others in need. When participants reported sterile supply stability was compromised, drug 
injecting equipment misuse took place.  The literature supports this occurs outside of 
SEPs, where having limited access to sterile syringes and homelessness increases the 
 69 
 
likelihood of sharing used equipment (Bozinoff et al., 2017; Munoz et al., 2015). Sterile 
supply stability issues brought about by fear of arrest or strong police presence may lead 
to increased sharing of used equipment (Flath et al., 2017; Munoz et al., 2015).  
SEPs should ensure services are easily accessible by considering neighborhood 
and built environment determinants such as SEP hours, locations, and PWID safety. The 
economic instability (including issues around transportation, the incompatibility of SEP 
hours and typical working hours) of SEP participants should be considered.  SEPs should 
continue working with police to ensure the threat of arrest and incarceration among 
participants is limited, and work with stakeholders to change drug paraphernalia laws. 
Policies protecting participant anonymity and setting boundaries with law enforcement 
are critical. It is important to consider economic stability in determining supply 
distribution models as those with the least stability appear to have the most difficulty 
maintaining adequate sterile supplies. 
Despite the education PWID in SEP receive, high-risk behaviors and attitudes 
persist around saving drugs for later use (a wash). Although the intent of using a wash is 
to avoid withdrawal symptoms, PWID may experience cotton fever, a flu-like illness 
resulting from contamination of used cotton filters with fungi or bacteria (Xie, Pope, & 
Hunter, 2015). Such an infection may lead to hospitalization and withdrawal. There is 
lack of recognition that injection equipment aside from the syringe becomes 
contaminated with viruses and bacteria that pose a risk for harm. Heimer et al. (2018) 
demonstrated hepatitis C virus can be transmitted in water from contaminated syringe to 
a cotton filter, and from the cotton filter into a new syringe. As such, it is important for 
PWID using SEP services to understand that the risk of acquiring infectious disease goes 
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beyond used syringe sharing. SEPs should work to continuously improve the health 
literacy of participants in an effort to avoid such health-related harms. 
Other high-risk behavior centers around injecting with others, especially intimate 
partners. Outside of SEP, Morris et al. (2014) noted a five times higher risk of receptive 
syringe reuse among intimate partners, leading to increased incidence in infections such 
as hepatitis C virus. Simmons, Rajan, and McMahon (2012) suggest that emotional and 
practical influences (such as convenience) contribute to intimate partner injecting. It is 
important for SEP participants to understand the risk of bacterial and viral contamination 
that occurs in used drug injecting equipment. SEPs must understand the needs of 
participants who inject with intimate partners may be different from those who do not. 
Exploring the social contexts in which each SEP participant injects could help staff 
determine which resources should be employed, and which educational components are 
offered. 
Future studies may look to replicate both the quantitative and qualitative findings 
at SEPs in other areas, as well as consider differences in SDOH among urban and rural 
PWID in SEP. Interventions can be developed to reduce the likelihood of intimate partner 
sharing and reuse. Policy changes using SDOH as a framework can be implemented to 
ensure PWID in SEP have access to ample sterile supplies, rather than limiting new 
supply distribution based on what is returned. Secondary exchange initiatives may be 
piloted, explored, and developed to help improve access to SEP services among PWID 
unable or unwilling to participate in the primary program, especially those with 
substantial difficulty with economic stability. Using SDOH as a framework for policy 
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development at the local level could provide meaningful changes. The SDOH may be 
used for future research to further explore PWID. 
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CHAPTER IV 
HARM REDUCTION, SYRINGE MISUSE, AND NURSING’S CODE OF ETHICS 
Executive Summary 
People who inject drugs (PWID) often face shortages in their sterile injecting 
equipment supply. They may use a number of strategies for acquiring sterile drug 
injecting equipment, including participation in harm reduction programs such as syringe 
exchange programs, engaging in pharmacy syringe sales, or purchasing sterile supplies 
from a drug dealer. In light of ongoing hepatitis C virus (HCV) infection and the opioid 
epidemics, harm reduction strategies that improve PWID access to sterile drug injecting 
equipment are critical. This policy brief describes ways in which PWID may access their 
sterile supplies, discusses the strengths and limitation of various supply acquisition 
approaches, highlights the ethical importance of harm reduction-based nursing care, and 
presents ideas for improving sterile supply access through nursing care. Incorporating 
harm reduction concepts into nursing care will help reduce health disparities among 
PWID, and may increase their ability to consistently use sterile injecting supplies with 
each injection episode. 
Introduction 
The concept of harm reduction was developed during the 1980s in response to the 
growing human immunodeficiency virus (HIV) epidemic, with rapid growth after HIV 
was linked to injection drug use. Harm reduction uses a pragmatic, non-judgmental 
approach to educating PWID on safer use practices, disease prevention, wound care, and 
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other areas such as legal needs, housing support, employment opportunities, and more 
(HRC, 2019). Table 1 displays the principles of harm reduction. 
Table 1 
Principles of Harm Reduction 
Principle 
1 Accept that drug use is part of reality, but work can be done to minimize its 
effects. Drug use should not be ignored, nor condemned.  
2 Understand that drug use encompasses a continuum of behaviors, from severe 
abuse to complete abstinence, and that there are safer ways of using drugs. 
3 Cessation of all drug use is not a criterion for measuring a successful policy or 
intervention; consider individual or community quality of life as a criterion for 
success. 
4 Encourage a non-judgmental and non-coercive approach to providing services 
(such as syringe exchange programs) in an effort to assist PWUD and their 
communities to reduce drug-related harm. 
5 Encourage PWUD to have a voice in the creation of programs and policies meant 
to benefit them, rather than having programs and policies created for them 
without input. 
6 Recognize PWUD are their own primary actors in reducing harms of their own 
use, and this encourages them to share information and support each other. 
7 Many social inequalities affect PWUD’s vulnerability and capacity to effectively 
manage drug-related harms. 
8 Harm reduction does not attempt to minimize or ignore the real threats and 
dangers associated with drug abuse, whether the drugs used are licit or illicit. 
Note. (HRC, 2019). 
Harm reduction tools include syringe exchange programs (SEP), syringe vending 
machines, secondary or peer exchange, and supervised injection facilities. Each harm 
reduction tool employs a basic program of supplying sterile drug injection equipment to 
PWID with the expectation used supplies will be returned for proper disposal. Education 
may be provided face-to-face, or in written materials. These programs have been shown 
to reduce the spread of infectious diseases such as hepatitis C virus (HCV) and HIV. The 
purpose of this policy brief is to explore the problem of sterile drug injection supply 
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access among PWID both in and outside of SEP programs, explore policy alternatives, 
and describe how nursing can ethically support such policy alternatives. 
Accessing Sterile Injecting Supplies 
Drug injecting supply access within SEP 
Multiple models of SEP supply distribution exist, and are briefly described in 
Table 2. There are variations in the types of supplies available at SEP as well, with some 
offering robust selections, and others only syringes. For example, SEPs in West Virginia 
and North Carolina may be limited to syringes and alcohol swabs. However, SEPs in the 
neighboring state of Kentucky have a wide assortment of available supplies such as 
filters, water, cookers, and alcohol swabs available (Bixler et al., 2018). Having 
availability of multiple choices for each type of equipment, including different sizes 
(gauge and needle length) of syringes and needs-based distribution models of SEP 
programs are considered best practice (NYC DHMH, 2009). Depending on where a SEP 
is accessed, participants may be able to acquire enough supplies to share with other 
PWID (secondary exchange), or conversely experience limitations on sterile supply 
access based on the quantity of syringes returned. 
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Table 2 
Syringe Exchange Program Distribution Models 
Model Program Description 
One-for-one exchange For each used syringe returned, participants may replace it 
with a sterile one.  
Less than one-for-one 
exchange 
Like one-for-one, this program requires an exchange of 
used-for-new syringes, but the syringes must originate 
from the SEP. For example, a syringe from a pharmacy can 
be returned after use, but it will not count towards a sterile 
replacement because it did not come from that particular 
SEP. 
One-for-one plus 
exchange 
Participants may exchange the number of syringes returned 
and take an additional pre-determined amount in an effort 
to build up a stable supply of sterile equipment between 
SEP visits. For example, a participant may return 20 
syringes and have 30 provided in exchange (plus 10). 
Needs-based Participants may obtain the number of sterile syringes 
needed without regard to the number of syringes returned. 
Participants are not limited on the frequency of their visits. 
This approach is considered best practice. 
Note: (Bluthenthal et al., 2007; Sherman et al., 2015). 
Drug injecting supply access outside of SEP 
When not participating in a SEP, PWID engage in a number of ways to secure 
sterile injecting supplies. Strategies include purchasing syringes and other needed 
supplies from a pharmacy, receiving supplies from a peer who is involved in SEP 
(secondary or peer exchange), trading drugs for sterile supplies, obtaining sterile 
equipment from their drug dealer, diverting syringes from patients with medical needs 
(like a diabetic on insulin), and more (Behrends, Li, & Gibson, 2017). How PWID obtain 
their sterile supplies influences their degree of syringe reuse, as described in the 
following paragraphs. 
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Pharmacy sales. 
In the United States, 23 states have legalized prescription sales of syringes to 
PWID (CDC, 2017). Figure 1 displays the distribution of states in which PWID might 
obtain supplies through a pharmacy. In several states, pharmacists are required to 
maintain a log of customer names, addresses, and the reported intended use of the 
syringes sold (Goodin., Fallin-Bennett, Green, & Freeman, 2018). Recording of such 
information is a barrier to some PWID, as anonymity is critical (Goodin et al., 2018). 
However, access to syringe sales through pharmacies is an important source for sterile 
supplies, and uptake of syringes from pharmacies has been seen nationwide (Zaller et al., 
2012). Importantly, some PWID purchasing syringes through pharmacies continue to 
engage in high-risk injection behavior, including reuse of used syringes (Zaller et al., 
2012; Zlotorzynska, Weidle, Paz-Bailey, & Broz, 2018). In a study of young PWID, up to 
49% reported reusing equipment despite access to pharmacy sales (Zaller et al., 2012). 
Studies have identified barriers such as stigma and denial of sales by pharmacists (despite 
legality) contribute to PWID avoidance or limiting of pharmacy syringe purchasing, but 
in areas with high drug use and overdose incidence, pharmacy sales are an integral part of 
harm reduction (Goodin et al., 2018; Meyerson et al., 2018). 
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Figure 1. Pharmacy syringe sales are legal in much of the United States. Delaware and 
Tennessee are the only states in which pharmacy syringe sales to PWID is explicitly 
illegal. Twenty-two states do not have a specific policy for or against syringe sales to 
PWID (CDC, 2017). 
Secondary or peer exchange.  
Participants in SEP obtain enough injecting supplies for themselves, but may also 
collect supplies to be distributed to other PWID. This practice is known as secondary 
exchange or peer exchange. Secondary exchange is common across the United States and 
serves as an opportunity for SEP harm reduction principles to reach PWID who might not 
directly engage in SEP services (Behrends et al., 2017). Brothers (2016) suggests there 
are a number of reasons PWID may not visit SEP, including distance, operating hours, 
disability, fear of police, fear of being identified, and feelings such as shame, anxiety, and 
stigma. PWID attending SEP who provide sterile supplies to other PWID serve important 
role in sterile supply access solutions (Behrends et al., 2017; Brothers, 2016). The SEP 
participants providing secondary exchange are often friends, family members, or intimate 
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partners of those receiving supplies as part of secondary exchange (Behrends et al., 
2017). Secondary exchange helps improve health equity because of its ability to reach 
PWID who might not otherwise have access to sterile drug injecting supplies and harm 
reduction education. 
Trade and drug dealer supply sales. 
Kuyper and colleagues (2006) described sterile syringe trade and sales among 
PWID, noting that such supplies may be obtained from medical patients such as 
diabetics, pharmacies, SEPs, or other PWID. In areas without SEP or before a SEP 
opened, many PWID reportedly obtained their injecting supplies through trading drugs 
for supplies, or by purchasing sterile supplies directly from their drug dealer (Kuyper et 
al., 2006). In Los Angeles, where SEP and pharmacy sales are legal, up to 16% of 
respondents reported obtaining their syringes from an unauthorized source (i.e. not a SEP 
or pharmacy) within the past six months (Quinn, Chu, Wenger, Bluthenthal, & Kral, 
2014). In Australia, syringes received through trade or dealers were typically in small 
amounts (four or less) (Bryant & Hopwood, 2009). Anecdotal reports from the SEP 
studied by Cave (2019) suggest trading syringes and supplies for drugs or acquiring 
syringes from dealers occurs despite SEP and pharmacy coverage in the area; however, 
little else is known as it has not been studied. 
Policy Alternatives: Increasing Access to a Consistent Supply of Sterile Equipment 
Despite the use of SEP or other means of acquiring drug injecting supplies, 
significant numbers of PWID share or reuse equipment (Behrends et al., 2017; Cave, 
2019; Des Jarlais et al., 2015; Flath, Tobin, King, Lee, & Latkin, 2017; Golub et al., 
2007). Reasons for sterile supply interruptions and challenges are numerous, and may 
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include difficulties with transportation (Canary et al., 2017; Cave, 2019), seasonal 
changes (Allen, Ruiz, Roess, & Jones, 2015), police presence or fear of arrest (Beletsky 
et al., 2014; Cave, 2019; Davis et al., 2019; Flath et al., 2017; Munoz, Burgos, Cuevas-
Mota, Teshale, & Garfein, 2015), and problems with SEP supply limits or operating 
hours (Bluthenthal et al., 2007; Cave, 2019; Davis et al., 2019). It is important to 
recognize there are a number of mechanisms that may help overcome such barriers, 
resulting in improved sterile injecting supply stability for PWID. These mechanisms 
include the use of sterile supply vending machines, utilizing mobile distribution units, 
scaling up secondary or peer exchange practices, eliminating one-for-one SEP 
restrictions, and increasing pharmacy coverage of sterile injecting supplies. Increased 
access to a consistent supply of sterile drug injecting equipment will improve the health 
of PWID. 
Vending Machines  
Syringe vending machines distribute sterile injecting supplies and serve as a 
return receptacle for used syringes (Philbin et al., 2009). They are used worldwide and 
may reduce SEP staffing costs, provide anonymity, allow 24/7 access, and may attract 
PWID who otherwise would not engage in harm reduction services (Philbin et al., 2009). 
Vending machines were first operational in the United States in Las Vegas, Nevada 
beginning in 2017 (O’Hara, 2017). The machines provide sterile injecting equipment, 
wound care kits, and safer sex kits. The machine supplies are free, but people wishing to 
use them must first register with a local harm reduction program to obtain a unique code 
that helps the program track machine and PWID interactions (O’Hara, 2017). During the 
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first year of the Las Vegas program, machines distributed 37,000 syringes to more than 
400 participants (Young, 2018). 
In Europe and Australia, where syringe vending machines have been used since 
1987, syringes are distributed after monetary payment or exchange of used syringes 
(Islam, Wodak, & Conigrave, 2008). Like the Las Vegas machines, European and 
Australian machines are stocked with healthcare items, but also have educational 
pamphlets (Islam et al., 2008). They have been shown to increase access to sterile 
injecting supplies, reduce incidence of used syringe sharing, increase access to health 
information and health services, and demonstrated safe syringe disposal (Islam et al., 
2008; Obadia, Feroni, Perrin, Vlahov, & Moatti, 1999). The machines may lead to cost 
savings, and are considered cost effective in their ability to reduce HIV and HCV 
transmission among PWID, even if the equipment was provided at no charge to the 
participant (Islam et al., 2008; Otiashvili, Kirtadze, Vardanashvili, Tabatadze, & Ober, 
2019). Public perception of the syringe vending machines is generally positive among 
Australians (White, Haber, & Day, 2016), and PWID report positive experiences with 
them in the country of Georgia (Otiashvili et al., 2019). There is some evidence that 
syringe vending machines reach PWID who would otherwise not access any type of harm 
reduction program (Islam & Conigrave, 2007). Currently, there is no literature describing 
perceptions/attitudes towards syringe vending machines among United States PWID or 
stakeholders. To-date, Las Vegas remains the only location in the United States utilizing 
this harm reduction strategy.   
Mobile Units 
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 SEP participants report location and transportation difficulties as reasons for not 
regularly attending. Strike and Miskovic (2018) conducted a literature review and 
provided a detailed description of mobile units providing SEP services, where traditional 
SEP services have been provided in brick and mortar, fixed locations. They included 
literature from the United States, Canada, and Russia to describe how mobile SEP units 
typically operate in a van or bus. Services provided by mobile units nearly mirrored fixed 
SEP services, although physical space may have been a reason for limiting some services 
such as HIV/HCV testing. Mobile units have the advantage of home delivery for disabled 
participants; they can quickly adapt their routes and service locations based on PWID 
demand or changes in police presence (Islam & Conigrave, 2007; Strike & Miskovic, 
2018). Limitations for mobile unit services include limited hours at a specific location 
may result in PWID missing services until the next scheduled stop in that location (Strike 
& Miskovic, 2018). This sentiment was reflected in work by this investigator (2019), 
where interview participants acknowledged past inconsistent interaction with mobile 
units due to limited service hours despite its convenient location. Nonetheless, mobile 
units are an effective way to improve sterile supply access and harm reduction service 
equity to PWID who might otherwise not engage in care (Islam & Conigrave, 2007).  
Support Secondary Exchange  
 At SEPs without quantity restrictions, like those in California, Europe, and 
Australia, secondary or peer exchange services are encouraged and recognized as a 
means to reaching PWID who would otherwise have limited access to sterile supplies 
(Newland, Newman, & Treloar, 2016). In California, 75-89% of SEP clients engage in 
secondary exchange, and 89% of SEPs in the United States as of 2007 supported the 
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activity (Behrends et al., 2017). In Baltimore, Maryland, nearly 65% of program syringes 
were distributed through secondary exchange (Behrends et al., 2017). The practice 
addresses SEP barriers such as limited operating hours, transportation difficulties, fear of 
police, protection of anonymity, and physical disability (Behrends et al., 2017; Brothers, 
2016). Benefits of secondary exchange do not exclusively address access to sterile 
supplies as many PWID serving as the peer exchanger also provide harm reduction 
education, information about overdose prevention, and assisting in referrals to medical 
and substance use treatment (Behrends et al., 2017). PWID reached by secondary 
exchangers include friends, family, intimate partners, and injecting drug customers 
(Brothers, 2016). Secondary exchange was reported by 56.8% (n=63) of SEP participants 
in a study by this investigator (2019), suggesting SEPs do not need to formally support 
secondary exchange in order for the behavior to occur. 
Although access to information and sterile supplies for non-SEP receivers of 
supplies is increased, secondary exchange has notable limitations. Evidence suggests 
those receiving supplies are still likely to reuse syringes and may choose to use 
equipment previously used by other people (Behrends et al., 2017). Not all secondary 
exchangers provide their equipment at no-cost to recipients (Brothers, 2016), which 
creates a potential barrier for some to acquire adequate sterile supplies due to economic 
instability. Trust is an important factor in willingness to receive supplies from others, so 
the potential reach of PWID suppling secondary exchange is limited to their individual 
networks (Bryant & Hopwood, 2009). Nonetheless, secondary exchange fills a critical 
void for many PWID to obtain sterile injecting supplies. 
Elimination of One-for-One and Less than One-for-One Exchange 
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One-for-one and less than one-for-one syringe exchange models are not best 
practice for harm reduction, and may lead to increased syringe and drug equipment reuse 
and sharing, as previously discussed. Existing SEPs that currently operate under these 
restrictive exchange models may find evidence-based practice a useful tool in changing 
policy to a needs-based model. Baltimore, Maryland is an excellent example of the 
impact moving from a less restrictive exchange policy (one-for-one) to the most 
restrictive policy (less than one-for-one), then back again (Sherman et al., 2015). During 
the time of most restriction, the SEP saw fewer new clients, and distributed and collected 
about half the number of syringes they had during the one-for-one exchange period 
(Sherman et al., 2015). During the most restrictive policy period, syringes were in 
circulation longer with the highest chances of being reused, resulting in public health 
concern for increased spread of infectious disease and other harms (Sherman et al., 2015). 
Conversely, less restrictive syringe dispensing policies have demonstrated reduced 
likelihood of syringe reuse and sharing (Bluthenthal et al., 2004; Kral, Anderson, Flynn, 
& Bluthenthal, 2004). 
Improving Pharmacy Coverage 
States and locales with legal access to syringes and injecting supplies at 
pharmacies have shown greater uptake of such services by PWID when compared to 
areas requiring a prescription to purchase syringes (Siddiqui et al., 2015). Pharmacies 
serve as an important source for PWID to obtain sterile injecting supplies, especially 
when SEP services are not legal (Meyerson et al., 2018; Siddiqui et al., 2015). Studies 
have also shown that the ability to purchase syringes without a prescription is associated 
with less syringe sharing among PWID (Sherman et al., 2015; Siddiqui et al., 2015). 
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Pharmacists have the potential to serve as harm reduction ambassadors in not only 
supplying sterile injection equipment, but also providing naloxone and overdose 
prevention education, HIV and HCV testing, and linkage-to-care for medical concerns 
including vaccinations (Rose, Lutnick, & Kral, 2014). In Kentucky, pharmacists have 
shown willingness to engage in harm reduction and syringe exchanges services, although 
community pharmacists favor the role more so than those from chain stores, which may 
lead to inequality among pharmacies (Goodin et al., 2018). Pharmacies serve as a critical 
access point for some PWID in terms of accessing sterile supplies, but more work is 
needed to ensure PWID are able to successfully complete a purchase and are not 
subjected to dissuasion, stigma, or discrimination by pharmacy staff (Chiarello, 2016; 
Goodin et al., 2018; Meyerson et al., 2018).  
Case Study 
The Commonwealth of Kentucky is facing dual epidemics: the spread of hepatitis 
C virus (HCV) infection, and the opioid epidemic. Syringe exchange programs were 
legalized in the state in 2015 in an effort to curtail the spread of infectious diseases 
among people who inject drugs (PWID), among other goals. There are now 69 approved 
SEP sites throughout the commonwealth. Even as these resources were made available, 
reports were made that SEP-supplied drug injecting equipment was being shared or 
reused among some SEP participants. Cave (2019) examined the frequency of, and 
factors associated with, drug injection equipment reuse and sharing using cross-sectional 
surveys (n=111) and estimated greater than 70% (n=78) of program participants 
personally reused equipment, regardless age and gender.. Cave (2019) also identified that 
more than 37% (n=42) of SEP participants received used injecting equipment from 
85 
others. Sharing of new equipment (secondary exchange) was common (56.8%, n=63), 
while sharing of used equipment was less-so (30.7%, n=34). In order to understand what 
influenced SEP participant’s equipment sharing and reuse behaviors, a qualitative study 
was conducted. Cave (2019) identified that unstable access to sterile injecting equipment 
supplies was a fundamental reason for SEP participants’ sharing and reuse of equipment, 
while the sharing of new equipment was done in the interest of keeping other PWID safe. 
Multidimensional factors that are best reflected by the social determinants of 
health (SDOH) model influenced subject’s ability to access sterile supplies at the SEP. 
Cave discovered the economic stability determinant impacted consistent, predictable 
transportation to the SEP, as well as the health/healthcare social determinant. Subjects 
with limited funds for bus or rideshare fares or fuel reported inconsistent time intervals 
between SEP visits that might leave them without any sterile supplies due to a longer 
than anticipated visit interval. Although many subjects understood one of the many 
benefits of SEP participation is a reduced risk of acquiring HIV or HCV infection, low 
health literacy contributed to unsafe syringe and other drug injecting equipment sharing 
and reuse practices, especially among intimate partners. The social/ community context 
health determinant kept some participants from routinely accessing SEP due to fear of 
loss of anonymity and arrest. 
Using a policy alternative such as eliminating restrictive SEP distribution models 
could help overcome these barriers by ensuring participants can acquire adequate or more 
than adequate sterile supplies, including supplies for secondary exchange purposes. 
Having adequate supplies allows participants to have flexibility in visit frequency and 
may reduce transportation hardships by increasing visit intervals. Furthermore, improving 
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access to sterile injecting supplies through bolstering pharmacy syringe sales and harm 
reduction education by pharmacists could improve sterile supply acquisition through 
location convenience and expanded operating hours. 
Nurses have the opportunity to support PWID in accessing sterile injection 
supplies. They can advocate for less restrictive SEP distribution policies and increased 
pharmacy syringe sales at the local level. Nurses can address SDOH when PWID present 
as patients by assessing health determinants, recognizing potential barriers to sterile 
supply acquisition, then advocating for alternatives and solutions, or supplying pragmatic 
education and strategies for overcoming barriers. Nurses are needed to support and 
advocate for harm reduction, especially access to sterile drug injecting supplies, which is 
supported by the American Nurses Association Code of Ethics. 
Harm Reduction and Nursing Ethics 
Canadian nurses have considered harm reduction in the context of the Canadian 
Nurses Association Code of Ethics, but application of the concept to the American 
Nurses Association Code of Ethics has not been described. In 2007, Pauly and colleagues 
described harm reduction and its alignment with the ethical standards for Canadian nurses 
across the principles of health and well-being, dignity, choice, and justice. The authors 
encouraged nurses to recognize how some drug policies adversely affect patient health 
and advocate for equitable change. They contend that criminalization of drug use has 
created unjust circumstances and environments for people who use drugs leading to poor 
health and negative social outcomes, and that nurses can empower patients by providing 
evidence-based information to improve safety. They also contend that all nurses should 
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insist on harm reduction strategies for individuals in all settings as they are in line with 
the code of ethics. 
The American Nurses Association (ANA) has published the Code of Ethics for 
Nurses with Interpretive Statements since 1950, and it has been through numerous 
revisions since that time (ANA, 2015). Like the Canadian code of ethics, the American 
code uses principles of well-being, dignity, choice and justice within several of the code’s 
provisions. In Table 3, this author identified pertinent ethical provisions in the 2015 
version of the Code and their application to people who use drugs, then paired them with 
related harm reduction principles. Examples of nursing care situations are described 
showing the relatedness between the Code of Ethics and harm reduction principles. 
Although the ANA has not specifically applied harm reduction to the code of 
ethics directly, they have described the role of nurses in the ongoing opioid epidemic in 
the United States (ANA, 2018). The ANA (2018) has recognized nurses are face-to-face 
with PWUD, and encourage nurses to provide pragmatic, harm-reduction based 
interventions and education to such people. Furthermore, the ANA (2018) supports nurse 
practitioners in prescribing medication assisted therapy, opioid prescribing training to 
prevent/recognize use behavior that may lead to patient addiction, learning to recognize 
patients at-risk for overdose death and providing naloxone prescriptions and naloxone 
training, and encourages work leading to safe disposal of unused medications. All of 
these ANA-encouraged approaches are consistent with harm reduction strategies and lead 
to improved health outcomes for PWUD. 
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Table 3 
ANA Code of Ethics Relationship to Harm Reduction Principles and Ethical Nursing Care for People Who Use Drugs 
Provision (ANA, 2015) Application to PWUD 
(Including PWID) 
Relevant Harm Reduction 
Principles (HRC, 2019) 
Ethical Nursing Application to the 
Care of PWUD (Including PWID) 
One: “The nurse 
practices with 
compassion and respect 
for the inherent dignity, 
worth, and unique 
attributes of every 
person.” 
Many nurses and healthcare 
professions have negative 
views of PWUD which 
leads to stigmatizing 
behaviors against such 
patients, and is a major 
barrier to accessing safe, 
quality, equitable healthcare 
for patients (Mundy, 2012).  
Recognize that drug use takes 
place and that it should not be 
ignored or condemned, but 
faced with pragmatic strategies 
that reduce harms.  
Cessation of drug use is not the 
standard for measuring success; 
improvements in quality of life 
and well-being are markers for 
showing such success. 
Nurses have a duty to avoid 
stigmatizing behavior that leads to 
reduced patient dignity, lack of 
respect, and increased patient harm. 
Providing education on how to access 
sterile injecting supplies through SEP, 
vending machines, secondary 
exchange, pharmacy sales, etc. is 
consistent with this provision. 
Providing such information in a 
dignified, respectful manner may lead 
to reduced harm. 
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Table 3 (continued). 
Provision (ANA, 2015) Application to PWUD 
(Including PWID) 
Relevant Harm Reduction 
Principle(s) (HRC, 2019) 
Ethical Nursing Application to the 
Care of PWUD (Including PWID) 
Three: “The nurse 
promotes, advocates for, 
and protects the rights, 
health, and safety of the 
patient.” 
SDOH may influence 
PWUD health literacy and 
ability to access healthcare, 
leading to unsafe injection 
practices, overdose, and 
other harms. 
Drug use encompasses a 
continuum of behaviors, and 
there are safer ways of using 
drugs.  
Focus on the health and safety 
of patients through strategies 
that reduce negative health 
consequences through safer use. 
Nurses are the primary educators in 
many healthcare settings, and are very 
well-equipped to provide PWUD with 
pragmatic education and approaches 
to improve drug injection technique, 
review the risk of harm with various 
routes of administration (inhaled via 
smoking or intranasal use versus 
injection or rectal administration), and 
strategies for infection prevention to 
reduce the incidence of skin and soft 
tissue infections, endocarditis, sepsis, 
and infectious diseases such as HIV 
and HCV. Nurses may further 
advocate for patient safety through 
overdose prevention education and 
ensuring access to naloxone for opioid 
users.  
Four: Discusses the role 
of the nurse in acting 
“consistent with the 
obligation to promote 
health and provide 
optimal care.” 
Ensuring PWUD are 
educated on harm reduction 
strategies effectively 
promotes health through 
reducing the risk of drug-
related harm while building 
a quality patient-nurse 
relationship leading to 
optimal care. 
Social inequalities, such as 
access to healthcare and health 
literacy, impact PWUD’s 
vulnerability and capacity to 
effectively manage drug-related 
harms.  
Building trust is a fundamental 
nursing skill; nurses have the ability to 
build trust with PWUD. Nurses may 
provide health promotion and optimal 
care by ensuring PWID understand 
drug-related harms and disease 
prevention. 
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Table 3 (continued). 
Provision (ANA, 2015) Application to PWUD 
(Including PWID) 
Relevant Harm Reduction 
Principles (HRC, 2019) 
Ethical Nursing Application to the 
Care of PWUD (Including PWID) 
Eight: Nurses should 
collaborate with other 
health professionals 
leading to reduced health 
disparities 
Health disparities are 
abundant for PWUD, where 
many have medical co-
morbidities in addition to 
addiction or mental health 
problems (Grebely, Dore, 
Morin, Rockstroh, & Klein, 
2017). Many PWUD are 
socioeconomically 
disadvantaged, have high 
frequency of mental health 
problems, encounter high 
rates of homelessness, and 
suffer from stigma (Grebely 
et al., 2017; Pauly, 2008).  
Social inequalities, such as 
access to healthcare and health 
literacy, impact PWUD’s 
vulnerability and capacity to 
effectively manage drug-related 
harms.  
Nurses should feel empowered to 
address health disparities, especially in 
collaboration with health allies. SEP 
services are provided by a 
combination of mental health 
specialists and social workers; nurses 
have the ability to navigate referral 
systems for social support, mental 
health support, and other healthcare 
needs such as reproduction, infectious 
disease services, and dental care. 
There are natural relationships 
between nurses and other healthcare 
providers; nurses should leverage 
these relationships to benefit PWID.  
Nine: Nurses “must 
articulate nursing values, 
maintain the integrity of 
the profession, and 
integrate principles of 
social justice into nursing 
and health policy.” 
For PWUD, social justice is 
difficult to come by. Pauly 
(2008) argues that for 
PWUD and harm reduction 
principles to reach social 
justice, PWUD, harm 
reduction providers, and 
nurses all need to come 
together to ensure policies 
are beneficial. 
Encourage PWUD to have a 
voice in the creation of 
programs and policies meant to 
benefit them, rather than having 
programs and policies created 
for them without input. 
Nurses are ethically obligated to 
ensure all patients have the 
opportunity to receive equal care, and 
ensure effective policies are in place 
that assure social justice. To help 
ensure social justice, PWUD should 
be included in program and policy 
development. Such work will increase 
equity of care and maintain the 
integrity of the nursing profession.    
Note: PWUD=people who use drugs; PWID= people who inject drugs 
90
 
91 
Discussion 
Some limitations should be considered in relation to this discussion. SEPs, non-
prescription syringe sales, and other harm reduction policies vary substantially from 
state-to-state, and often from locale to locale. Such diverse approaches to the problem of 
ensuring PWID have consistent access to sterile injecting supplies limits the ability of 
this author to locate all relevant exemplars and policies. Several articles presented were 
qualitative in nature and may not fully represent the magnitude of effects on sterile 
injecting supply acquisition or PWID behavior. Critical data specific to Kentucky’s 
PWID was not available in regard to uptake of pharmacy syringe sales and degree of SEP 
participation in rural settings. 
Policy Recommendations 
To prevent the spread of HIV, HCV, and other infectious disease as well as 
mitigate potential harms associated with injecting drugs with unsterile, used equipment, it 
is critical for PWID to have consistent access to sterile drug injecting equipment. A 
number of strategies to obtain sterile equipment have been employed across the United 
States for decades, with needs-based models of syringe exchange programs 
demonstrating the ability to consistently reduce drug-related infection and harm. PWID 
can benefit from ensuring consistent access to sterile injecting supplies, especially 
syringes, through reduced restrictions on SEP distribution models and formal support for 
secondary exchange. Nurses should be educated on local syringe supply access and 
acquisition strategies in order to provide needed information to PWID in their care, and 
recognize the ethical obligation to do so. 
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Given the high risk of acquiring HIV or HCV through injection drug use, it is 
especially important to consider best practices in harm reduction and syringe exchange 
services. Any SEP services are preferred over no services, but one-for-one or less than 
one-for-one exchanges do not have the public health benefits that less restrictive policies 
demonstrate. As community stakeholders, nurses should advocate for existing SEPs to 
adopt the least restrictive syringe exchange policy as it should reduce the time and 
number of used syringes in circulation. Nurses working with their community will 
recognize the needs of PWID vary, but support for SEP services helps permit secondary 
exchange practices for otherwise unreachable populations, and is in line with CDC 
recommendations (Abdul-Quader et al., 2013; Behrends et al., 2017; Davis et al., 2019). 
The PWID participating in this investigator’s (2019) study were supportive of the one-
for-one plus model used in their SEP, but acknowledged they often ran out of sterile 
supplies due to barriers reflected by SDOH leading to unexpected secondary exchange, 
difficulty with SEP hours or transportation, and more. A needs-based syringe exchange 
approach is best practice (NYC DHMH, 2009), and ensures that PWID have consistent 
access to sterile injecting equipment. Nurses can work alongside PWID at the local level 
to help overcome challenges to sterile injecting supply acquisition. 
Reducing restrictions among SEP distribution models may build upon existing 
programs and relationships, and may reduce public health costs through increased 
prevention of infectious disease. Certainly, moving to a needs-based syringe exchange 
model could help the problem of sterile supply access for the participants in this 
investigator’s (2019) study because it may lead to: 1) fewer SEP visits resulting in 
reduced transportation difficulties; 2) consistent sterile supply availability for those 
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engaging in secondary exchange, whether planned or unplanned; 3) recognition that 
PWID experience inconsistent motivation to use only sterile equipment, and that 
procrastination plays a role in not returning at regular intervals; and 4) reduced demand 
on SEP participants time in relation to the need for frequent visits. Future policy changes 
may wish to consider sterile supply distribution via vending machines and improved 
implementation of non-prescription syringe sales at pharmacies.  
Nurses should recognize that harm reduction approaches are generally well-
received by PWUD, but access to harm reduction services may be limited (Davis et al., 
2019). A number of resources to assist nurses with incorporating harm reduction 
strategies into clinical care are available (ANA, 2018; Drug Policy Alliance, 2019; HRC, 
2019). Without solid understanding and use of harm reduction strategies, it will be 
difficult for American nurses to fully support PWUD in the context of continued health 
disparities. Nurses should use ethical guidance as a means to reflect on their approach to 
the care of PWUD and recognize that harm reduction principles pair well with the ANA 
Code of Ethics (2015). In time, nurses should feel comfortable recommending harm 
reduction strategies to PWUD as part of routine patient care, including information about 
syringe exchange programs, secondary exchange, pharmacy syringe sales, and more. 
Such evidence-based, cost-effective, and ethical strategies help to ameliorate the harms 
faced by PWUD (Bartlett et al., 2013; Drucker et al., 2016; Nguyen et al., 2014). Without 
harm reduction in patient care, PWUD may not receive the full spectrum of pragmatic 
education required to reduce the spread of infectious disease, reduce the risk of 
endocarditis or skin and soft tissue infections, and other health-related harms. Harm 
reduction is equitable healthcare.  
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Future work using harm reduction strategies and principles should begin with 
implementation of healthcare policies and approaches for nurses caring for PWUD. Both 
nurses and PWUD should be part of policy development, and they should aim to ensure 
nurses are competent in the care of PWUD, the nature of the nurse-patient relationship is 
free from stigma, and that community harm reduction services are accessible. Emphasis 
on improving access to sterile drug injecting supplies should be paramount, as this is a 
key issue in PWID syringe reuse and sharing behavior. Nurses should increase their 
awareness of harm reduction by incorporating the concept into nursing curricula and 
continuing education. Recall that development of trust is critical for PWUD engaging in 
harm reduction: nurses may develop and validate tools measuring nursing attitudes and 
beliefs towards various aspects of harm reduction and adapt education and policies 
accordingly. Educational programs that improve nurse-PWUD relationships within a 
harm reduction framework, supported by the SDOH model, may improve the quality and 
equity of care PWUD receive. Future work should also explore areas in which harm 
reduction is failing, and find ways to determine the root cause for its failure. 
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CHAPTER V 
CONCLUSION 
People who inject drugs (PWID) face many problems in trying to acquire a 
consistent supply of sterile drug injecting equipment. The principles of harm reduction 
are meant to provide guidance on ways to protect this vulnerable group from social, legal, 
and health-related harms. Harm reduction focused on prevention of negative health 
outcomes may be practiced in many settings—from healthcare provider offices and 
hospitals, to syringe exchange programs (SEPs), to supervised injection facilities, and 
more. Chapter II outlined harm reduction in detail, and provided some evidence that 
PWID generally have positive perceptions of harm reduction. Best practice guidelines for 
syringe exchange programs use the harm reduction principles to support PWID engaging 
in such services. Not all models of SEPs fulfill the recommend best practices, which may 
lead to failure to fulfill all potential benefits of harm reduction. The social determinants 
of health (SDOH) model is a useful tool and has been used to study PWID. In nursing, 
SDOH has been used in quality improvement to better engage PWID in care 
coordination. 
Chapter III utilized the SDOH model as a conceptual underpinning for the study 
aimed at estimating the prevalence of syringe and injecting equipment sharing and reuse 
among PWID participating in a SEP. The urban SEP used a one-for-one plus exchange 
model, and had received reports that participants were not using sterile drug injecting 
equipment for 100% of their injecting episodes. The author found rates of 
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personal syringe reuse, reuse of equipment previously used by others, and rates of sharing 
used equipment were common. The SDOH contributed to subject’s inconsistent access to 
a stable sterile drug injecting supply, even when SEP participants were aware of some of 
the harms associated with reuse of drug injecting equipment. Subjects were clear that 
they valued personal and public safety despite the harms associated with injection drug 
use, but SDOH could supersede their ability to maintain consistent harm reduction 
practices (such as injecting with someone of the same serostatus when sterile supplies are 
not available due to supply access difficulty). Future work should aim to discover 
interventions to limit sharing of equipment between intimate partners, examining the 
impact of implementing full support of secondary exchange and a needs-based 
distribution model, and identifying ways to overcome SDOH barriers such as limited 
transportation limited PWID understanding of or engagement in health and healthcare. 
The policy brief presented in Chapter IV highlights some of the difficulties PWID 
have in accessing a consistent source of sterile drug injecting equipment. It reviewed 
methods of supply acquisition for PWID who are both involved and not involved in 
SEPs. Opportunities exist to bolster sterile supply access to PWID outside of SEP 
through supply vending machines, increased pharmacy supply sales and harm reduction 
support, and supporting secondary syringe exchange among PWID peers. Moving to a 
needs-based supply distribution model within SEPs could have a significant impact on 
PWID who are adversely affected by SDOH. The concept of harm reduction is important 
not only for PWID, but for those caring for this population. The nursing code of ethics is 
in line with harm reduction principles; nurses should feel empowered to help PWID 
overcome SDOH and/or sterile injecting supply access issues. 
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Implications for this body of work include recognition that PWID are faced with 
many challenges in achieving full use of harm reduction practices. Nurses have the 
opportunity and ethical obligation to provide harm reduction education and care 
coordination and assistance in helping PWID access sterile drug injecting equipment. 
Models of SEP sterile supply distribution that limit PWID access to all of the needed 
supplies is problematic, especially for PWID who face disadvantages from a SDOH 
perspective. Additionally, a needs-based distribution of drug injecting supplies and 
increased harm reduction principle implementation across all healthcare settings should 
be implemented as it has been shown to improve health outcomes and is ethical practice. 
Overall limitations include the possibility that all related publications were not 
discovered due to the search strategy used and multiple synonyms across search terms. 
Time constraints made it difficult to explore alternative literature resources such as gray 
literature, editorials, and work published outside of journals. Research participants were 
self-selected, and limited reports were available to compare/contrast findings. 
Future directions for research may use the SDOH model as a tool to identify 
issues and improve access to harm reduction services. Common SDOH barriers should be 
addressed with policy change recommendations. A replication study among PWID in a 
rural SEP should be considered in order to compare drug injecting equipment misuse 
prevalence estimates to those in this urban sample, and to qualitatively examine potential 
differences in behaviors and barriers among rural PWID. Future policy work should aim 
to improve access to sterile drug injecting equipment through any of the means presented, 
but also consider new avenues of supply delivery.  
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APPENDIX C: INTERVIEW GUIDE 
Examining Syringe and Drug Injection Equipment Sharing and Re-use Among
People Who Inject Drugs Participating in a Syringe Exchange Program 
Interview Guide 
Introduction: I have invited you here today to participate in research that will help me and
others to understand the behaviors of individuals  who participate in a syringe exchange 
program re-use personal equipment, use other’s equipment, or share used injection 
equipment with others. This session will last 45-60 minutes and will be audio recorded to 
ensure we capture what you think is important. Neither you nor your comments will be 
identified. 
Domains 
Study Aim 3 
Primary Questions Probes/ Secondary Questions 
(if needed) 
Procurement 
How one obtains sterile 
syringes, water, cookers, 
cotton, and other needed
equipment to perform sterile 
injection 
Tell me about your 
experiences in 
obtaining sterile 
injecting equipment. 
What is easy/difficult about
continuing to use only sterile 
equipment? 
What might help you or people 
you know who inject drugs stop
reusing or sharing their used
syringes and equipment?  
Personal re-use 
Using a personally used
syringe or pieces of injection 
equipment again. Items have 
not been shared with anyone. 
What might cause you
to re-use your own 
syringe/ equipment? 
What prompts you to re-use 
your own equipment? 
What happens when you decide 
to use only sterile equipment? 
What factors might keep you
from using a sterile 
syringe/equipment 100% of the 
time? 
Receptive re-use 
Being the recipient of a 
syringe/injection equipment 
previously used by another 
person, regardless of the age 
of equipment, number of 
uses, or cleaning procedures 
Tell me about a time 
you used equipment 
previously used by 
another person. 
What motivated you to do this? 
What was going on at the time? 
Tell me what might be done 
through the syringe exchange 
program or other program to
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APPENDIX D: SURVEY 
Please take a moment to complete this short, confidential survey.  The results will help us improve our services for 
you and others who use the syringe exchange program.   
Your ability to participate in the syringe exchange will not be affected in any way by your answers or your decision 
on whether or not to complete this survey. 
1.  What is your age (in years)?
________________________ 
2.  Are you…?
 Male 
 Female 
 Transgender – ID Female 
 Transgender – ID Male 
 I self-identify as __________________ 
3.  Which of the following best describes you?  Check
all that apply. 
 White, non-Hispanic 
 Black, non-Hispanic  
 Hispanic/Latino/Latina 
 Other (please specify) 
____________________ 
4.  How often do you visit a syringe exchange program?
 This is my first time 
 Less than once per month (Less than monthly) 
 1-3 times most months (monthly or almost 
monthly) 
 1-4 times most weeks (weekly or almost 
weekly) 
 5-7 times most weeks (daily or almost daily) 
5.  How often do you share your used syringes,
cookers, cotton, water, or any items used to prepare 
your injection with other people? (You used these 
items first, then shared them.) 
 Never 
 Less than once per month (less than 
monthly)  
 1-3 times most months (monthly or almost 
monthly) 
 1-4 times most weeks (weekly or almost 
weekly) 
 5-7 times most weeks (daily or almost daily) 
6.  How often do you share NEW syringes, cookers,
cotton, water, or any items used to prepare your 
injection with other people? (Do you share extra, 
unused equipment, or pick up extra equipment to give 
to people who did not go to the syringe exchange?) 
 Never 
 Less than once per month (less than monthly) 
 1-3 times most months (monthly or almost 
monthly) 
 1-4 times most weeks (weekly or almost 
weekly) 
 5-7 times most weeks (daily or almost daily) 
7. How often do you use syringes, cookers, cotton,
water, or any items used to prepare your injection 
previously used by other people? (These items were 
used and given to you after they had been used.) 
 Never 
 Less than once per month (less than 
monthly)  
 1-3 times most months (monthly or almost 
monthly) 
 1-4 times most weeks (weekly or almost 
weekly) 
 5-7 times most weeks (daily or almost daily) 
8.  How often do you re-use your own syringes,
cookers, cotton, water, or any items used to prepare 
your injection?  
 Never 
 Less than once per month (Less than monthly) 
 1-3 times most months (monthly or almost 
monthly) 
 1-4 times most weeks (weekly or almost 
weekly) 
 5-7 times most weeks (daily or almost daily) 
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APPENDIX E: PREAMBLE 
Examining Syringe and Drug Injection Equipment Sharing and Re-use Among People 
Participating in a Syringe Exchange Program 
Date: ____________ 
This study is about learning how often people who inject drugs who are participating in a syringe 
exchange program share or re-use their injection equipment with others, and it has been approved 
by the University of Louisville Institutional Review Board. You are being invited to participate in 
this research study by providing the information on the attached survey. The survey will take 
approximately 3 minutes time to complete.  
Information provided by you will be added to the information provided by others. It will be 
mathematically analyzed to estimate the rates of syringe and injection equipment sharing and re-
use. The information collected may not benefit you directly. The information learned in this study 
may be helpful to others.   
Taking part in this study is voluntary. The Health Insurance Portability and Accountability 
Act of 1996 (HIPAA) provides federal safeguards for your protected health information 
(PHI). State and federal privacy laws also may also require your health information to be 
protected. By taking part in this survey, you provide your permission, called your 
“authorization,” for the use and disclosure of PHI. If you participate, the research team 
working on this study may use and share your health information to answer the research 
questions described in this document, and to make sure that the research was done 
correctly. This includes things learned from the procedures described in this consent form. 
Your health information may be shared with a public health authority that is authorized by 
law to collect or receive such information for the purpose of preventing or controlling 
disease, injury, or disability, and conducting public health surveillance, investigations or 
interventions. The time period when information can be used or shared ends when all 
activities related to this study are completed. By answering survey questions, you agree to 
take part in this research study. You do not have to answer any questions that make you 
uncomfortable. You may choose not to take part at all. If you decide to be in this study you may 
stop taking part at any time. If you decide not to be in this study or if you stop taking part at any 
time, you will not lose any benefits for which you may qualify.  
There are no significant research-related risks, but you may experience psychological discomfort 
(feelings of guilt, shame, embarrassment). The survey does not contain any information that 
will identify you, and the Louisville Metro Department of Public Health will not know of 
your survey participation in this study. 
Individuals from the University of Louisville, the Louisville Metro Department of Public Heath, 
the Institutional Review Board (IRB), the Human Subjects Protection Program Office (HSPPO),  
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and other regulatory agencies may inspect the survey records. In all other respects, however, the 
data will be held in confidence to the extent permitted by law. Should the data be published, your 
identity will not be disclosed.  
If you have any questions, concerns, or complaints about the research study, please contact: 
Barbra Cave at 502-852-2010  
If you have any questions about your rights as a research subject, you may call the Human Subjects 
Protection Program Office at (502) 852-5188. You can discuss any questions about your rights as 
a research subject, in private, with a member of the Institutional Review Board (IRB). You may 
also call this number if you have other questions about the research, and you cannot reach the study 
doctor, or want to talk to someone else. The IRB is an independent committee made up of people 
from the University community, staff of the institutions, as well as people from the community not 
connected with these institutions. The IRB has reviewed this research study.  
If you have concerns or complaints about the research or research staff and you do not wish to give 
your name, you may call 1-877-852-1167. This is a 24-hour hot line answered by people who do 
not work at University of Louisville.  
Thank you, 
Barbra Cave, APRN, Vicki Hines-Martin, PhD, RN, FAAN, M. Celeste Shawler, PhD, Rachel 
Vickers Smith, PhD, MPH, and Laura Smart, MD 
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APPENDIX F: INFORMED CONSENT 
Subject Informed Consent Document 
EXAMINING SYRINGE AND DRUG INJECTION EQUIPMENT MISUSE 
AMONG PEOPLE WHO INJECT DRUGS PARTICIPATING IN A SYRINGE 
EXCHANGE PROGRAM 
Investigators name & address: Vicki Hines-Martin, PhD, RN, FAAN 
School of Nursing 
University of Louisville 
4055 K Building 
555 S. Floyd St.  
Louisville, KY 40202 
Barbra Cave, MSN, APRN, FNP-BC, PhDc 
Clinical Trials Unit 
University of Louisville 
401 E. Chestnut St. Suite 460 
Louisville, KY 40202 
M. Celeste Shawler, PhD, PMHCNS-BC 
School of Nursing 
University of Louisville 
4038 K Building 
555 S. Floyd St.  
Louisville, KY 40202 
Rachel Vickers Smith, PhD, MPH 
School of Nursing 
University of Louisville 
4058 K Building 
555 S. Floyd St.  
Louisville, KY 40202 
Laura Smart, MD 
School of Medicine Division of Gastroenterology, 
Hepatology & Nutrition 
University of Louisville 
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550 S. Jackson St.  
Third Floor 
Louisville, KY 40202 
Study sponsor: University of Louisville School of Nursing 
Site where the study is to be conducted: Louisville Metro Department of Public Health 
and Wellness, 400 E. Gray St. Louisville, KY 40202 
Phone number for subjects to call with questions: 502-852-2010 
Introduction and Background Information 
You are invited to participate in a research study. The study is being conducted by Dr. 
Vicki Hines-Martin, Barbra Cave, Dr. Celeste Shawler, Dr. Rachel Vickers Smith, and 
Dr. Laura Smart. The study is sponsored by the University of Louisville School of 
Nursing. The study will take place at the Louisville Metro Department of Public Health 
and Wellness, 400 E. Gray St., Louisville, Kentucky. Approximately 20 subjects will be 
invited to participate. 
Purpose 
The purpose of this study is to explore the motivations and behaviors of people who 
inject drugs using a syringe exchange program who share or re-use syringes and drug 
injection equipment. 
Procedures 
In this study you will be interviewed in a private session expected to last 45-60 minutes. 
The interview will take place in a private room in the Louisville Metro Department of 
Public Health and Wellness. The interview will be led by one of the members of the 
study team. The interviewer will ask you to share through thoughts and experiences about 
syringe and injection drug equipment sharing and re-use while participating in a syringe 
exchange program. The interviewer is a member of the study team and will use an 
interview guide to begin and guide the discussion. You do not have to answer any 
questions that make you uncomfortable. The interview will be audio recorded to make 
sure that all points identified in the interview are accurate. The entire study will last about 
six months. 
Potential Risks 
There are no foreseeable risks other than possible breach of confidentiality, legal 
problems, and discomfort in answering personal questions. There may also be 
unforeseen risks.  
Benefits 
The information collected may not benefit you directly. The information learned in this 
study may be helpful to others.  
Compensation 
No compensation is available for your participation in this study. 
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HIPAA Research Authorization  
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides 
federal safeguards for your protected health information (PHI). State and federal privacy 
laws also may also require your health information to be protected. By signing this form, 
you provide your permission, called your “authorization,” for the use and disclosure of 
PHI.  
If you sign this form, the research team working on this study will use and share your 
health information to answer the research questions described in this document, and to 
make sure that the research was done correctly. This includes things learned from the 
procedures described in this consent form. They may also collect other information 
including your name, address, date of birth, medical history, and other information from 
your medical records from this institution and other institutions involved with this 
research, as well as from your other healthcare providers (which may include information 
about HIV status, drug, alcohol or STD treatment, genetic test results, or mental health 
treatment). Those persons who receive your health information may not be required by 
Federal privacy laws (such as the HIPAA Privacy Rule) to protect it and may share your 
information with others without your permission, if permitted by laws governing them.  
In most cases, the health information that identifies you can be used or shared by the 
research team only if you give your permission by signing this form. Your health 
information may be shared with a public health authority that is authorized by law to 
collect or receive such information for the purpose of preventing or controlling disease, 
injury, or disability, and conducting public health surveillance, investigations or 
interventions.  
The time period when information can be used or shared ends when all activities related 
to this study are completed. 
Revocation of Research Authorization 
You may withdraw the authorization you have given to use and share your protected 
health information at any time. This means you can tell us to stop using and sharing your 
protected health information. If you withdraw/revoke your authorization:  
• We will stop collecting information about you.
• You may not withdraw information that we had before you told us to stop.
• We may already have used it or shared it.
• We may need it to complete the research.
• We may need it to search records that are available to the public.
1Staff may ask your permission to follow-up with you if there is a medical reason to do 
so.  
To withdraw your authorization, you will be requested to complete a written “Revocation 
of Research Authorization” form located at the end of this document. You may also 
obtain a copy from your study doctor, designated personnel or from the Human Subjects 
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Protections Program Office website 
(https://louisville.edu/research/humansubjects/templates/biomedical-forms) 
Confidentiality 
Total privacy cannot be guaranteed. Your privacy will be protected to the extent 
permitted by law. If the results from this study are published, your name will not be made 
public. While unlikely, the following may look at study records: 
The University of Louisville Institutional Review Board, and Human Subjects 
Protection Program Office, and/or the Office of Human Research Protections (OHRP). 
This research is covered by a Certificate of Confidentiality from the National Institutes of 
Health. The researchers with this Certificate may not disclose or use information or 
documents that may identify you in any federal, state, or local civil, criminal, 
administrative, legislative, or other action, suit, or proceeding, or be used as evidence. 
Information or documents protected by this Certificate cannot be disclosed to anyone else 
who is not connected with the research except, if there is a federal, state, or local law that 
requires disclosure (such as to report child abuse, but not for federal, state, or local civil, 
criminal, administrative, legislative, or other proceedings) if you have consented to the 
disclosure, or if it is used for other scientific research, as allowed by federal regulations 
protecting research subjects. If you report child abuse, or the intent to harm yourself or 
others, the investigator is legally required to report such information which may result in 
a breach of confidentiality and legal problems. 
You should understand that a Certificate of Confidentiality does not prevent you from 
voluntarily releasing information about yourself or your involvement in this research. If 
you want your research information released to any other person not connected with the 
research, you must provide consent to allow the researchers to release it. 
Security 
Your information will be kept private by placing it in a secure, locked cabinet and a 
password protected computer accessible only by members of the study team.  
Voluntary Participation 
Taking part in this study is voluntary. You may choose not to take part at all. If you 
decide to be in this study you may stop taking part at any time. If you decide not be in 
this study or if you stop taking part at any time, you will not lose any benefits for which 
you may qualify. It will not impact your relationship with the University of Louisville or 
the Louisville Metro Department of Public health.  
Contact Persons, Research Subject’s Rights, Questions Concerns, and Complaints 
If you have any concerns or complaints about the study or the study staff, you have three 
options.  
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You may contact the principal investigators, Barbra Cave, at 502-852-2010 or 
barbra.cave@louisville.edu or Vicki Hines-Martin at 502-852-8511 or 
vphine01@louisville.edu  
If you have any questions about your rights as a study subject, questions, concerns or 
complaints, you may call the Human Subjects Protection Program Office (HSPPO) at 
502-852-5188. You may discuss any questions about tour rights as a subject, in secret, 
with a member of the Institutional Review Board (IRB) or HSPPO staff. The IRB is an 
independent committee composed of members of the University community, staff of the 
institutions, as well as lay members of the community not connected with these 
institutions. The IRB has reviewed this study.  
If you want to speak to a person outside the University, you may call 1-977-852-1167. 
You will be given the chance to talk about any questions, concerns, or complaints in 
secret. This is a 24-hour hotline answered by people who do not work at the University of 
Louisville.  
Acknowledgement and Signatures 
This informed consent document is not a contract. This document tells you what will 
happen during the study if you choose to take part. Your signature indicates that this 
study has been explained to you, that your questions have been answered, and that you 
agree to take part in the study. You are not giving up any legal rights to which you are 
entitled by signing this informed consent document. You will be given a copy of this 
consent form to keep for your records.  
Subject Name (please print) Signature of Subject   Date 
Printed Name of Legal Representative Signature of Legal Representative     Date 
(if applicable)     
Relationship of Legal Representative to Subject 
Printed Name of Person Explaining Signature of Person Explaining         Date 
Consent Form  Consent Form (if other than Investigator) 
Printed Name of Investigator Signature of Investigator Date 
130 
List of Investigators: Phone Numbers: 
Vicki Hines-Martin 502-852-8511 
Barbra Cave  502-852-2010 
Celeste Shawler 502-852-8391 
Rachel Vickers Smith 502-852-8510 
Laura Smart   502-852-6991 
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CURRICULUM VITAE 
Barbra A. Cave, MSN, APRN, FNP-BC 
956 Willow Creek Lane 
Louisville, KY 40245 
502-648-9904 
Barbra.Cave@louisville.edu 
EDUCATION 
University of Louisville, Louisville, KY 
School of Nursing, MSN to PhD Program 
Anticipated Graduation Date: October 2019 
Bellarmine University, Louisville, KY 
Donna & Allan Lansing School of Nursing, Family Nurse Practitioner 
Master of Science in Nursing, August 2010 
Bellarmine University, Louisville, KY 
Donna & Allan Lansing School of Nursing, Accelerated BSN 
Bachelor of Science in Nursing, December 2005  
Bellarmine University, Louisville, KY 
Bellarmine College of Arts & Sciences, Biology 
Bachelor of Arts, May 2003  
PROFESSIONAL EXPERIENCE 
May 2015-Present 
University of Louisville, Family Nurse Practitioner, Louisville, KY  
Serving in the Clinical Trials Unit as sub-investigator or coordinator for clinical trials 
involving Hepatology and Gastroenterology (0.2 FTE) and providing specialty 
hepatology care for patients as lead provider in the Jewish Hospital Hepatitis C 
Treatment Clinic June 2015-June 2017 and as Hep C Program Lead for the University of 
Louisville Hospital Hep C Center July 2017-present (0.6 FTE). Clinical trial duties 
include physical exams, Fibroscan assessment, screening and recruitment, lab review, site 
initiation visit attendance, and reporting. Duties within the NP-led Hep C Center include 
consulting with and evaluating HCV patients for treatment, prescribing treatment, 
Fibroscan, monitoring/reviewing labs, reviewing liver biopsies and various tests while 
132 
maintaining standard of care. Comprehensive Hepatology care for special/difficult to 
treat populations such as those with co-infections, liver transplant, renal disease, or 
cirrhosis is provided within the Hep C Center. Serving as a hepatology consultant for 
primary care providers wishing to treat hepatitis C infection through the Kentucky 
Hepatitis Academic Mentorship Program (KHAMP). Assisted Gastroenterology 
Associates, part of KentuckyOne Health, from August through December 2015 by 
providing general gastroenterology care. Responsibilities there included assessment and 
treatment of Inflammatory Bowel Disease, IBS, Diarrhea/Constipation, and common GI 
complaints. 
May 2016-August 2016 
Robley Rex Veterans Affairs Hospital, Family Nurse Practitioner, Louisville, KY. 
(FEE basis, 0.2 FTE) Providing specialized care for Veterans with Chronic Hepatitis C 
with duties including liver assessment, physical exams, lab/Fibroscan, viral resistance 
mutation analyses, medical imaging, and prescribing treatment. 
January 2012-February 2015 
University of Louisville Physicians, Family Nurse Practitioner, Louisville, KY  
Provided outpatient healthcare services for patients of the University of Louisville’s 
Division of Gastroenterology, Hepatology, and Nutrition. Patient duties included health 
management, ordering and interpreting tests, reviewing medical imaging, and prescribing 
medication and treatments with emphasis on Hepatitis C, cirrhosis, IBD, and hospital 
follow-ups, including those with serious and acute illness. Assisted clinical research 
faculty/staff as Sub-Investigator on numerous clinical trials, including physical exams, 
result reviews, and attendance at Investigator Meetings. Additional activities included 
attendance at weekly Medical Grand Rounds, GI/Hepatology Grand Rounds, and other 
research and clinical meetings as appropriate. Assisted faculty physicians in facilitating 
patient-physician communication, and evaluating acutely-ill patients when requested. 
Played an integral role in the opening of the Healthcare Outpatient Center outpatient 
infusion services center. 
October 2010- December 2011 
University Children’s Kidney Specialists, Family Nurse Practitioner, Louisville, KY 
Provided specialized nephrology care to pediatric and adolescent patients.  
Preformed urinalysis, ordered/interpreted labs and imaging, prescribed medication as  
necessary. Educated families on the natural history and treatment of pediatric kidney  
diseases, including dietary modifications, treatment expectations, renal transplantation, 
and medication regimens. Coordinated Pediatric Nephrology Multidisciplinary Team  
meetings for complex chronic patients with a goal of providing patient-specific,  
multidisciplinary care for patients pre- and post-transplant, or progressing to ESRD. 
January 2006-October 2010 
Jewish Hospital & St. Mary’s Healthcare, Staff Nurse, Louisville, KY 
ICU South, Clinical Ladder Level III. Specialized in adult critical care including 
neuroscience and solid organ transplantation with emphasis on liver and kidney. 
Experienced in sepsis/multisystem organ dysfunction, peri-operative care, and palliative 
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care. Specialized training on VAD (Heartmate, Heartmate VTE, Heartmate II), CRRT, 
IABP, ICP monitors, and ventilators. Served as new-hire and student preceptor, Member 
of Skin Care Committee, and Nursing Ambassadors.  
October 2008-October 2010 
Isaacs & Isaacs Law Firm, Registered Nurse Consultant, Louisville, KY 
Reviewed medical records as needed to determine if client cases/claims are supported by 
documentation. Organized complex medical case files into time lines, related diagnoses, 
and re-presented the information in a useful manner for attorney and courtroom use. 
CERTIFICATIONS    
American Nurses Credentialing Center (ANCC), Family Nurse Practitioner, 
Board Certified since September 2010. 
American Heart Association BLS certified, December 2004-Present. 
American Heart Association ACLS certified, December 2006-December 2010 and July 
2015-Present. 
Modified Rankin Scale Certified, University of Glasgow, April 2016-Present 
Certified Critical Care Registered Nurse (CCRN), February 2008-February 2011. 
MEMBERSHIP ORGANIZATIONS 
American Association for the Study of Liver Disease (AASLD),  
Hepatology Associate Member since July 2012. Hepatology Associates Committee 
Member 2019-present. Member of the 2015-2019 AASLD Liver Meeting Midlevel 
Professionals Behavioral and Quality Issues: Practice Issues abstract review team,  
abstract review chair 2019. Participated as an abstract reviewer for DDW 2016-19.  
Sigma Theta Tau International Iota Zeta Chapter of the Honor Society of Nursing,  
University of Louisville, member since January 2018. Lambda Psi Chapter of the Honor 
Society of Nursing, Bellarmine University, inducted October 2010. 
American Association of Nurse Practitioners (AANP), member since April 2015. 
Kentucky Coalition of Nurse Practitioners and Nurse Midwives (KCNPNM), 
member since August 2009. 
Association of Community Health Nursing Educators (ACNHE), member April 
2018-April 2019. 
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American Association of Critical-Care Nurses (AACN), member November 2007-
November 2010. 
 
 
FACULTY  
 
Gastroenterology/Hepatology Advanced Practice Providers (GHAPP), Faculty,  
March 2018-Present. In conjunction with the CLDF, GHAPP serves to provide peer- 
developed and led learning opportunities for nurse practitioners and physician assistants  
specializing in in gastroenterology and/or hepatology.  
 
Kentucky Hepatitis Academic Mentorship Program (KHAMP), Faculty and planning 
committee member, March 2018-Present. KHAMP goals include establishing a primary 
care provider network trained by hepatitis C experts who can complete the HCV care 
continuum from screening to cure, and to remove barriers to care for patients living with 
hepatitis C in rural/underserved communities.  
 
Chronic Liver Disease Foundation (CLDF), HCV Faculty, April 2017-Present. CLDF 
is a non-profit organization that provides educational programs to physicians, nurses, 
nurse practitioners, physician assistants, and pharmacists to provide the most up-to-date 
information surrounding liver diseases available.  
 
Scripps Clinic Liver Research Consortium, CME Faculty, March 2016-Present.  
The SC Liver Research Consortium is committed to the education of health care 
providers treating patients with liver disease, regardless of background or practice setting. 
Topics include nonalcoholic fatty liver disease, hepatocellular carcinoma, primary biliary 
cholangitis, primary sclerosing cholangitis, and viral hepatitis. 
 
 
GRANT FUNDING 
  
Harm Reduction Coalition/Gilead HepConnect Grant, Principal Investigator. 
Funded September 2019-present. This educational grant allows for development and  
distribution of harm reduction education for nurses and nurse practitioners across  
Kentucky. The program incorporates non-nurse stakeholders, including people who use  
drugs. 18 months funding: $100,000 
 
Gilead Frontlines of Communities in the United States (FOCUS), Principal 
Investigator. Funded December 2017-Present. This grant allows for universal HCV 
screening at UofL Hospital Labor & Delivery and creates registries to follow both 
infected mothers and exposed infants to the primary outcomes: HCV cure for mothers 
and confirmation of HCV infection or clearance in the child. Second year project includes 
HCV screening expansion to the ULH emergency department with goals of linking all 
HCV-infected adults to care. First year funding: $193,372. Second year funding: 
$313,812. 
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Study Tours on Infection Prevention and Control (IPC) Best Practices for Egyptian 
Medical Professionals, Institute of International Education (IIE) US Agency for 
International Development (USAID). PI: Ruth Carrico, PhD, DNP, APRN. Serving as 
Co-Investigator and focusing on hepatitis C virus infection prevention, control, and 
treatment; October-December 2018. Grant award: $272,511 
PEER-REVIEWED JOURNAL PUBLICATIONS 
Crittenden, N. E., Buchanan, L. A., Pinkston, C. M., Cave, B., Barve, A.... 
& Kuns‐Adkins, C.B. (2016). Simeprevir and sofosbuvir with or without ribavirin to treat 
recurrent genotype 1 hepatitis C virus infection after orthotopic liver  
transplantation. Liver Transplantation. PMID 26915588 
Reddy, K., Patrick, C., Liaquat, H., Rodriquez, E., Stocker, A., Cave, B., …Abell, T. 
(2018). Differences in referral access to gastrointestinal subspecialty patients: Barriers 
and opportunities. Health Equity 2(1). doi: 10.1089/heq.2018.0001  
PUBLISHED ABSTRACTS 
Cave, B.A., Higdon, K., Pasquenza, N., & Espinosa, C.M. (2019, October). Factors 
associated with linkage-to-care after delivery. To be published in Hepatology (70)4. 
Hoboken, NJ: Wiley-Blackwell. 
Crittenden, N., Davis, E. G., Marsano, L. S., McClain, C. J., Barve, A., Goshko, B. A., & 
Cave, M. C. (2014, January). Single center experience with simeprevir/sofosbuvir  
combination therapy for recurrent hepatitis C virus infection in liver transplant recipients. 
In Hepatology (Vol. 60, p. 700A). Hoboken, NJ: Wiley-Blackwell. 
CONFERENCE PRESENTATIONS 
Cave, B.A. “HCV: Current state and elimination strategies” presented at the 2019  
Gastroenterology/Hepatology Advance Practice Providers Conference in Las Vegas, NV 
on September 6, 2019. (Podium) 
Cave, B.A. “Quick assessment and management of viral hepatitis” presented at the 2019 
University of Louisville Hospital Advanced Practice Provider Conference in Louisville, 
KY on August 23, 2019. (Podium) 
Cave, B.A, “KHAMP: The role of expert mentoring in hepatitis C elimination” Presented 
at the 6th Annual Kentucky Viral Hepatitis Conference on July 31, 2019 in Lexington, 
KY. (Podium) 
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Cave, B.A, “UofL FOCUS: HCV care navigation for mothers and infants” Presented at 
the 6th Annual Kentucky Viral Hepatitis Conference on July 31, 2019 in Lexington, KY. 
(Podium) 
Cave, B.A. “Trifecta! Kentucky leads in viral hepatitis A, B, & C” Presented at the 2019 
Kentucky Coalition of Nurse Practitioners and Nurse Midwives Conference on April 24, 
2019 in Covington, KY. (Podium) 
Cave, B.A., Sanders, K.J., Wilburn, A., Barve, A.J., Hill, B.L. … & Espinosa, C. (2019, 
February). “Scaling up HCV care in Appalachia: The Kentucky Hepatitis Academic 
Mentorship Program (KHAMP)” presented at the AASLD/IDSA Special HCV 
Conference in Miami, FL on February 1, 2019. (Poster) 
Cave, B.A., Pasquenza, N., Higdon, K., Davis, D.W., & Espinosa, C. (2018, October). 
“Care navigation for moms and babies after reactive universal hepatitis C virus 
screening.” Presented at Research! Louisville on October 10, 2018 in Louisville, KY. 
Abstract #NS 6. Winner of the 2018 UofL School of Nursing Graduate Poster Award. 
Cave, B.A. & Hanson, C. “Recent Hepatitis C Treatment Advances” presented at the 
inaugural Gastroenterology/Hepatology Advance Practice Providers Conference in Las 
Vegas, NV on September 7, 2018. (Podium) 
Cave, B.A. “The Next Era in Hepatitis C Treatment: Bringing Cure to Primary Care”  
presented at the Center for Health, Education, and Research in Morehead, KY on August 
7, 2018. (Podium) 
Cave, B.A., & Revert, D.H. (2018). “Best Practices in HCV Diagnosis and Linkage to 
Care” presented at the 5th Annual Kentucky Viral Hepatitis Conference in Lexington, KY 
on July 31, 2018. (Podium) 
Cave, B.A. “NASH: From Steatosis to Cirrhosis” presented at the 30th Annual Kentucky 
Coalition of Nurse Practitioners and Nurse Midwives Conference on April 20, 2018 
(Podium) 
Cave, B.A., Beeber, H., Sanders, K.J., O’Donnell, J. & Smart, L. (2017, September). 
“Large-scale hepatitis C screening and the changing epidemiology of hepatitis C in 
Kentucky.” Research! Louisville 2017 in Louisville, KY. Abstract #NS 3. Winner of the 
2017 UofL School of Nursing Graduate Poster Award. 
Cave, B.A. “Justifying the Cure: Kentucky’s Drug Users Should Have Access to HCV 
Treatment” presented at the 4th Annual Kentucky Viral Hepatitis Conference in 
Lexington, KY on July 27, 2017 (Podium) 
Cave, B.A. “Advocacy and Access: When Your Patient Needs an Oil Change” presented 
at the 4th Annual Kentucky Viral Hepatitis Conference in Lexington, KY on July 27, 
2017 (Podium) 
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Cave, B.A. “The New Age of Hepatitis C: Diagnosis and Treatment” (Abstract# 
9197387)  presented at the 29th Annual Kentucky Coalition of Nurse Practitioners and 
Nurse Midwives Conference on April 20, 2017 in Covington, KY (Podium) 
 
Cave, B.A. “Hepatitis C Treatment Access and Advocacy” (revised from 2015) presented 
at the 3rd Annual Kentucky Viral Hepatitis Conference in Lexington, KY on July 26, 
2016.  http://chfs.ky.gov/dph/diseases/Hepatitis+C.htm (Podium) 
 
Cave, B.A. “The Viral Hepatitis Epidemic in Kentucky” presented at the Kentucky 
Public Health Association Annual Conference, Owensboro, KY on April 12, 2016. 
(Podium) 
 
Cave, B.A. “Hepatitis C: Diagnosis, Treatment, and Linkage to Care” presented at the 
Kentucky Academy of Physician Assistants annual CME Symposium event, Lexington, 
KY, on November 5, 2015. http://kentuckypa.org/events-cme/2015-kapa-cme-
symposium (Podium) 
 
Cave, B.A., Lunn, S. M., Smart, L.E., Sanders, K.J., Cave, M.C., Carrico, R.M. (2015, 
October).”Viral Hepatitis Screening at the 2015 Kentucky State Fair Determined a Rate 
of Hepatitis C Infection Approximately Three Times the National Average.” Research! 
Louisville 2015 in Louisville, KY. Abstract #RS-82 (Poster) 
 
Goshko, B.A. “Hepatitis C Treatment Access and Advocacy” presented at the 2nd Annual 
Kentucky Viral Hepatitis Conference, Lexington, KY on July 28, 2015.  
 
Goshko, B.A. “Viral Hepatitis: Alphabet Soup” presented at the Kentucky Coalition of 
Nurse Practitioners and Nurse Midwives 27th Annual Conference, Covington, KY, April 
25, 2015. (Podium) 
 
 
CONSULTING  
 
Dova Pharmaceuticals, Avatrombopag Advisory Committee, January 2018-March 
2019. 
 
 
ADVISORY BOARD MODERATNG 
 
Abbvie: Assessing the needs of new HCV treaters, Chicago, IL; December 2018. 
 
 
SPEAKER BUREAUS 
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Gilead, Sovaldi (sofosbuvir), October 2013-Present, Harvoni (sofosbuvir/ledipasvir), 
October 2014-Present, Epclusa (sofosbuvir/velpatasvir) June 2016-Present, Vosevi 
(sofosbuvir/velpatasvir/voxilaprevir) July 2017-Present. 
Abbvie, Humira (adalimumab), January 2014-December 2018; Viekira Pak (ombitasvir, 
ritonavir, dasabuvir, and paritaprevir), December 2014-July 2017; Technivie (ombitasvir, 
paritaprevir, and ritonavir), July 2015-July 2017, Mavyret (glecaprevir/pribentasvir) July 
2017-Present. 
Merck, Zepatier (elbasvir/grazoprevir), February 2016-September 2017. 
Bristol Myers Squibb, Daklinza (daclatasvir), June 2015-August 2016. 
Salix, Xifaxan (rifaxamin) and Relistor (methylnaltrexone), November 2012-January 
2016, and Xifaxan (rifaximin) January-December 2018. 
Entera Health, Enteragam (serum-derived bovine immunoglobulin/protein isolate), 
March 2015-March 2016. 
Janssen, National Speaker on Simponi (golimumab), June 2014-March 2016: Assisted 
with deck development and served as faculty presenter for an updated Simponi deck in 
February 2015. Olysio (simeprevir) December 2013-October 2015. Remicade 
(infliximab) February 2015-March 2016. 
Vertex, Incivek (telaprevir), January 2013-November 2013. 
CLINICAL TRIALS 
Co-Primary Investigator 386540: Analysis of Hepatitis C Data from the Screening 
Performed at the Kentucky State Fair. 15.0748 
Sub-Investigator 0151003(ANDANTE): A Double-Blind, Randomized, Placebo-
Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PD-04236921 in 
Subjects with Crohn's Disease who are Anti-TNF Inadequate Responders 11.0228. 
B0151005 (ADANTE II): Extension study. 11.0467 
Sub-Investigator TU100P2T2 - A Multi-Center, Randomized, Double-Blinded, Placebo-
Controlled Study of Daikenchuto (TU-100) in Subject with Moderate Crohn's Disease. 
11.0568 (Completed) 
Sub-Investigator CNDO 201-003: A Phase II Study to Evaluate the Efficacy and Safety 
of 12 Weeks of Treatment with Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as 
compared to Placebo, Followed by a 12 Week Open-Label Treatment Period in Patients 
with Moderately to Severely Active Crohn's Disease 12.0364 (Completed) 
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Sub-Investigator CNT01275CRD3003 (IMUNITI): A Phase 3, Randomized, Double-
blind, Placebo Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and 
Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely 
Active Crohn's Disease 11.0476 (Completed) 
 
Sub-Investigator Protocol CNTO1275CRD3002 (UNITI-2) / A Phase 3, Randomized, 
Double—blind, Placebo—controlled, Parallel—group, Multicenter Study to Evaluate the 
Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to 
Severely Active Crohn´s Disease 13.0362 (Completed) 
 
Sub-Investigator IM129-005: A Phase IIb Randomized, Placebo-Controlled Study to 
Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with 
BMS-936557 in Subjects with Active Ulcerative Colitis (UC) 11.0226 (Completed) 
 
Sub-Investigator MK5172-038: A Phase II Randomized, Dose Ranging, Clinical Trial to 
Evaluate the Safety, Tolerability and Efficacy of Different Doses of MK5172 when 
Administered Concomitantly with Peginterferon alpa-2b and Ribavirin in Treatment 
Naive Subjects with Chronic Hepatitis C Virus Infection 12.0564 (Completed) 
 
Sub-Investigator MK5172-068: A Phase III Randomized Clinical Trial to Study the 
Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who 
have Failed Prior Treatment with PEGylated Interferon and Ribavirin (P/R) with 
Chronic HCV GT1, GT4, GT5, and GT6 Infection 12.0424 
 
Sub-Investigator Protocol MK5172-017-00: A Long-Term Follow-up Study to Evaluate 
the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with 
Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior 
Clinical Trial 12.0512 
 
Sub-Investigator MK5172-PN-003: A Randomized, Active-Controlled, Dose-Ranging 
Estimation Study to Evaluate the Safety, Tolerability and Efficacy of Different Regimens 
of MD-5172 when Administered Concomitantly with Peginterferon alfa-2b and Ribavirin 
in Treatment-Naive Patients with Chronic Genotype 1 Hepatitis C Virus Infection 
11.0301 (Completed) 
 
Sub-Investigator Novel Therapies for Alcoholic Hepatitis 12.0427 
 
Sub-Investigator PO7755(MK-3034-040-01): A Phase 3, Safety and Efficacy Study of 
Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC 
Subjects 12.0383 (Completed) 
 
Sub-Investigator Protocol 27018966IBS3001: A Randomized, Double-blind, Placebo-
controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-
27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel 
Syndrome 12.0226 (Completed) 
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Sub-Investigator Protocol ACT12688: A Randomized, Double-blind, Placebo-
controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients 
with Active Moderate to Severe Ulcerative Colitis (UC) 13.0339 (Completed) 
Sub-Investigator Protocol IDN-6556-02 / A Placebo-Controlled, Multicenter, Double-
Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in 
Subjects with Acute-on-Chronic Liver Failure (Conatus) 13.0976 (Completed) 
Sub-Investigator Protocol C13008: A Phase 3, Open-label Study to Determine the 
Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative 
Colitis and Crohn’s Disease 08.0515 
Sub-Investigator Protocol LUM001-201: A Phase 2, Randomized, Double-Blind, 
Placebo-Controlled Study to Evaluate LUM001, an Apical Sodium-Dependent Bile Acid 
Transporter Inhibitor (ASBTi) in Combination with Ursodeoxycholic Acid (UDCA) in 
Patients with Primary Biliary Cirrhosis 13.0288 (Completed) 
Sub-Investigator Merit-UC: Randomized, Double Blind, Prospective Trial Investigating 
the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in 
Ulcerative Colitis (Methotrexate Response in Treatment of UC-Merit-UC) 12.0246  
Sub-Investigator Protocol MK-3415A-002 (MODIFY II): A Phase III, Randomized, 
Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of a 
Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and 
MK-3415A (Human Monoclonal Antibodies to C. difficile toxin A and B) in Patients 
Receiving Antibiotic Therapy for C. difficile Infection 12.0028 (Completed) 
Sub-Investigator CLARITY-1: A Balanced, Randomized, Placebo-Controlled, Double-
Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related 
Hearing Loss 14.1295 (Completed) 
Sub-Investigator Receptos Ulcerative Colitis Open Label Extension: A Phase 3, 
Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to 
Severe Ulcerative Colitis 15.0688 
Independent Assessor CONCERNT-HF: A Phase II, Randomized, Placebo-Controlled 
Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and 
c-kit+ Cardiac Stem Cells, Alone or in combination, Administered Transendocardially in 
Subjects with Ischemic Heart Failure 15.0733 
Sub-Investigator Hep C with Simeprevir, Sofosbuvir, and Ribavirin: A Retrospective 
Review of the Treatment of Hepatitis C Virus Genotype 1 Patients with Simeprevir, 
Sofosbuvir, With and Without Ribavirin at University of Louisville/Jewish Hospital 
14.1239 
Sub-Investigator Protocol IDN-6556-07 (Conatus-POLT): A Multicenter, Double-
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Blind, Randomized Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) 
Reinfection and Liver Fibrosis or Cirrhosis Following Orthotopic Liver Transplantation 
for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic 
Response Following anti-HCV Therapy 15.0242 
 
Sub-Investigator GED-0301-CD-001 (Celgene Crohn’s) - A Randomized, Double-
Blind, Multicenter Study To Explore The Effect Of Ged-0301 On Endoscopic And 
Clinical Outcomes In Subjects With Active Crohn’s Disease 15.0186 
 
Sub-Investigator Protocol M13-740 / A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic 
Remission in Subjects with Moderately to Severely Active Crohn's Disease who have 
Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy 
15.0141 
 
Sub-Investigator Novartis PBC: CLJN452X2201 A multi-part, randomized, double-
blind, placebo-controlled study to assess the safety, tolerability, and efficacy of LJN452 
in Patients with Primary Biliary Cirrhosis 15.0809 
 
Sub-Investigator Xpert HCV VL Assay: Clinical Evaluation of the Xpert HCV VL Assay 
15.0305 (Completed) 
 
Sub-Investigator Protocol GA29144 Open-Label Crohn’s Disease: An Open-Label 
Extension and Safety Monitoring Study of Patients with Moderately to Severely Active 
Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III 15.0375 
 
Sub-Investigator Gilead 0102 Primary Sclerosing Cholangitis: GS-US-321-0102/A 
Phase 2b, Dose-ranging, Randomized, Double-Blind, Placebo-Controlled Trial 
Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl 
Oxidase-Like 2 (LOXL2), in Subjects with Primary Sclerosing Cholangitis (PSC) 13.0517 
 
Sub-Investigator Gilead 0105 Advanced Liver Fibrosis: GS-US-321-0105/A Phase 2b, 
Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the 
Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 
(LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-
Alcoholic Steatohepatitis (NASH) 13.0518 
 
Sub-Investigator Gilead 0106 Compensated Cirrhosis: GS-US-321-0106/A Phase 2b, 
Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the 
Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 
(LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic 
Steatohepatitis (NASH) 13.0539 
 
Independent Assessor Heartmate III (MOMENTUM 3): Multi-Center Study of MagLev 
Technology in Patients Undergoing MCS Therapy with Heartmate 3 15.0347 
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Sub-Investigator Protocol CNTO1275UCO3001 (UNIFI): A Phase 3, Randomized, 
Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the 
Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with 
Moderately to Severely Active Ulcerative Colitis 15.0638 
Independent Assessor SENECA: A Phase I, First-in-Human, Multicenter, Randomized, 
Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogenic 
Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced 
Cardiomyopathy 15.0928 
Sub-Investigator PERSEUS Tobira: A Phase 2 Proof of Concept Study Investigating 
the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary 
Sclerosing Cholangitis (PSC) 16.0015 
Sub-Investigator Roche GA28951:  An Open-Label Extension and Safety Monitoring 
Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in 
Etrolizumab Phase III Studies 14.0533 
Sub-Investigator Protocol 652-2-203 (Tobira NASH): CENTAUR-Efficacy and Safety 
Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in 
Adult Subjects with Liver Fibrosis 14.1274 
Sub-Investigator Protocol 747-302 (Intercept PBC): A Phase 3b, Double-Blind, 
Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obetacholic 
Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis 14.1228  
Sub-Investigator Protocol 747-303 (Intercept NASH): A Phase 3, Double-Blind, 
Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety 
and Efficacy of Obetacholic Acid in Subjects with Nonalcoholic Steatohepatitis (NASH) 
15.0879 
Sub-Investigator Protocol APD334-003 Arena Ulcerative Colitis: A Phase 2, 
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to 
Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely 
Active Ulcerative Colitis 15.0696 (Completed) 
Sub-Investigator Protocol CC-10004-UC-001 Celgene Ulcerative Colitis: A Phase 2, 
randomized, placebo-controlled, multicenter study to investigate the efficacy and safety 
of apremilast (CC-10004) for treatment of subjects with active ulcerative colitis 14.1249 
Sub-Investigator Protocol GA28948: Phase III, Randomized, Double-Blind, Double-
Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of 
Remission) and Safety of Etrolizumab Compared with Adalimumab and Placebo in 
Patients with Moderate to Severe Ulcerative Colitis Who Are Naïve to TNF Inhibitors 
14.0881 
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Sub-Investigator Protocol GA28950: Phase III, Double-Blind, Placebo-Controlled, 
Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and 
Maintenance in Patients with Moderate to Severe Ulcerative Colitis Who Are Refractor 
or Intolerant of TNF Inhibitors 14.0220 
Sub-Investigator Protocol GA29144: A Phase III, Randomized, Double-Blind, Placebo-
Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an 
Induction and Maintenance Treatment for Patients with Moderately to Severely Active 
Crohn’s Disease 15.0252 
Sub-Investigator Protocol GS-US-326-1100 (Gilead UC): A Combined Phase 2/3, 
Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study 
Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely 
Active Ulcerative Colitis 15.0904 
Sub-Investigator and Coordinator Protocol IDN-6556-10 (Conatus Cirrhosis): A 
Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability 
and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis 14.0613 (Completed) 
Sub-Investigator and Coordinator Protocol IDN-6556-02 (Conatus): A Placebo-
Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and 
Pharmacodynamic Trial of IDN-6556 in Subjects with Acute-on-Chronic Liver Failure 
13.0976 (Completed) 
Sub-Investigator RPC01-301 (Receptos 3101 UC): A Phase 3, Multicenter, 
Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and 
Maintenance Therapy for Moderate to Severe Ulcerative Colitis 15.0586 
Sub-Investigator Protocol BAY 86-9766: A prospective, single-arm, multicenter, 
uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with 
RAS mutant Hepatocellular Carcinoma (HCC) 13.0432 (Completed) 
Sub-Investigator PF-05285401: A Phase 2 Randomized, Double-Blind, Placebo-
Controlled, Parallel Group, Multi-center Study to Investigate the Safety and Efficacy of 
MultiStem (PF-05285401) in Subjects with Moderate to Severe Ulcerative Colitis 
10.0594 (Completed) 
Sub-Investigator Protocol HVB-02-13 (HBV Assay): Multicenter, Prospective 
Evaluation of the Beckman Coulter DxN HBV Viral Load Assay as an Aid in the 
Management of HBV-infected Individuals Undergoing Antiviral Therapy 14.0236 
(Completed) 
Sub-Investigator Protocol LTS12593 (Sanofi Extension): A multicenter single-arm 
open-label extension study evaluating the long-term safety and tolerability of SAR339658 
in patients with Ulcerative Colitis (UC) 13.0875 (Completed) 
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Sub-Investigator Protocol D5170C00002 (MedImmune Crohn’s): Phase 2b Double-
blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of 
MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or 
Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy 16.0093 
Sub-Investigator Protocol IDN-6556-12 (Conatus NASH): A Multicenter, Randomized, 
Double-blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase 
Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis 16.0115 
Sub-Investigator PIONEER-CD: A Randomized, Double-Blind, Placebo-Controlled 
Trial to Evaluate the Effectiveness of a Nutritional Intervention in Improving the 
Intestinal Mucosal Health Status in Subjects with Crohn’s Disease (CD) Receiving 
Induction Anti-TNF Therapy 16.0616 
Sub-Investigator GFT505-315-1 (GENFIT NASH): A Multicenter, Randomized, 
Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of 
Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis 16.0637 
Sub-Investigator Protocol SHP626-201 (Shire NASH): A Phase 2 Double-Blind, 
Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability 
and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter 
Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis 16.0666 
Sub-Investigator Protocol GS-US-366-1992: A Phase 3b Randomized, Open-label, 
Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of 
Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who 
Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or 
Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV 
Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet 
Antiviral Regimens) 16.0799 
SERVICE 
Bellarmine University Alumni Board of Directors¸ Louisville, Kentucky  
Executive Committee, Ex-Officio 2016-2017, Alumni Association President 2015-2016, 
Vice-President 2014-2015.Young Alumni Committee, June 2009-2014. Committee Chair 
2012-2014. 
Amateur Athletic Union, TaeKwonDo Certified Official, Class C, 2014-2015; Class D 
2013. AAU member 2001-Present. 
River TaeKwonDo, Black Belt and Instructor, 5th Dan, 1999-Present. 
National Kidney Foundation Gift of Life Gala Board, Louisville Chapter, Logistics 
Committee, October 2011-March 2014. 
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